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Abstract (max 300 words) 55 
Recent advances in highly multiplexed immunoassays have allowed systematic large-scale 56 
measurement of hundreds of plasma proteins in large cohort studies. In combination with genotyping, 57 
such studies offer the prospect to 1) identify mechanisms involved with regulation of protein 58 
expression in plasma, and 2) determine whether the plasma proteins are likely to be causally 59 
implicated in disease.  We report here the results of genome-wide association (GWA) studies of 83 60 
proteins considered relevant to cardiovascular disease (CVD), measured in 3,394 individuals with 61 
multiple CVD risk factors. We identified 79 genome-wide significant (p<5e-8) association signals, 55 62 
of which replicated at P<0.0007 in separate validation studies (n=2,639 individuals). Using automated 63 
text mining, manual curation, and network-based methods incorporating information on expression 64 
quantitative trait loci (eQTL), we propose plausible causal mechanisms for 25 trans-acting loci, 65 
including a potential post-translational regulation of stem cell factor by matrix metalloproteinase 9 66 
and receptor-ligand pairs such as RANK-RANK ligand. Using public GWA study data, we further 67 
evaluate all 79 loci for their causal effect on coronary artery disease, and highlight several potentially 68 
causal associations. Overall, a majority of the plasma proteins studied showed evidence of regulation 69 
at the genetic level. Our results enable future studies of the causal architecture of human disease, 70 
which in turn should aid discovery of new drug targets.  71 
  72 
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Author Summary (150-200 words) 73 
Several proteins that circulate in blood have been linked to cardiovascular disease through the use of 74 
classic epidemiology and correlation studies. If individuals with higher risk of disease have higher 75 
levels of a protein, the protein may be associated with disease. However, this does not necessarily 76 
mean that the protein causes disease; it may merely be an innocent bystander or a consequence of the 77 
disease process. To establish whether a protein causes disease, a genetic approach, insensitive to 78 
reverse causation, can be used. Instead of correlating the levels of the protein itself, gene variants that 79 
regulate the protein levels are used in the analysis.  This approach requires prior knowledge of which 80 
genetic variants are linked to individual proteins. Therefore we completed a map of how common 81 
genetic variants affect the blood concentration levels of 83 proteins that have been implicated in 82 
cardiovascular disease. By using this map of cause-to-effect findings, we gained insights into the 83 
regulation of a majority of the proteins under study and how they relate to risk of coronary artery 84 
disease. This study provides a map of genetic regulation of important cardiovascular plasma proteins, 85 
insights into their upstream regulatory environment, as well as novel leads for cardiovascular drug 86 
development. 87 
  88 
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Introduction 89 
Cardiovascular disease (CVD), especially coronary artery disease (CAD) is a leading cause of human 90 
morbidity and mortality. Data from the world health organization (WHO) showed that CVD caused 91 
approximately 17.5 million deaths in 2012, corresponding to 31% of all deaths globally. Of these 7.4 92 
million were estimated to be due to coronary heart disease and 6.7 million to stroke [1]. 93 
Specific and mechanistically relevant biomarkers are important tools in risk prediction, disease 94 
diagnosis and successful development of new therapies [2]. Proteins in the circulation have been 95 
extensively explored as biomarkers across numerous disease conditions, not least because of the 96 
relative ease with which blood plasma and serum can be accessed, stored and analysed in 97 
observational studies and randomized controlled trials.  98 
The usefulness of a plasma biomarker in disease prediction, or as surrogate endpoint in a clinical trial, 99 
depends on its specificity and sensitivity. These metrics reflect the relationship of the biomarker with 100 
a pre-specified disease endpoint, but are inherently influenced by biological factors such as the tissue 101 
expression, stability, regulation and variability of the biomarker. The genetic contribution to the 102 
variability of plasma biomarkers can be explored in genome-wide association (GWA) studies using 103 
single nucleotide polymorphisms (SNPs), and this approach has been applied to uncover numerous 104 
such relationships [3–5]. For distinct plasma biomarkers such as circulating proteins, the associations 105 
are also known as protein quantitative trait loci (pQTLs) [6–9].  106 
Genetic loci for biomarkers and pQTLs have wide applicability in research. Firstly, pQTLs in trans 107 
can identify previously unknown regulatory pathways. Using trans-pQTLs to discover regulatory 108 
pathways is beneficial because it is based on in-vivo human observations that have well-established 109 
direction of causality, flowing from SNP to protein [7]. This approach has been extensively used in-110 
vitro, for example in yeast studies [8], and the overall goal of such analysis is a deeper understanding 111 
of the regulatory check-points giving rise to a particularly biomarker concentration. For a biomarker 112 
that is causally involved in disease, e.g. low-density lipoprotein cholesterol (LDL-C), this is crucial 113 
knowledge as it allows targeting of upstream factors, e.g. HMG-CoA reductase. 114 
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Secondly, GWA study loci associated with circulating levels of plasma biomarkers that are predictive 115 
of disease risk enable evaluation of whether the biomarker association with disease is likely to be a 116 
causal relationship, using Mendelian randomization (MR). For example, although both c-reactive 117 
protein (CRP) and LDL-C predict risk of CVD and are lowered by treatment with statins, MR studies 118 
have concluded that plasma LDL-C is an aetiologically important factor, while plasma CRP is a 119 
biomarker that is not causally related to CVD [10,11]. Similarly, all efforts towards HDL-cholesterol 120 
lowering drugs have failed, consistent with MR results showing that SNPs affecting HDL-levels are 121 
unrelated to risk of CVD [12]. Based on these experiences of pharmacological treatment lowering the 122 
LDL-C concentration, one may suggest that a biomarker which is both predictive and causal provides 123 
a more attractive target for novel therapeutics. Numerous associations between biomarkers and 124 
disease have been described in the literature, but the potential causal involvement of these biomarkers 125 
has only been addressed for a limited number, partly due to a lack of robust genetic predictors for 126 
many plasma proteins. 127 
In the present study, we analyzed 83 plasma proteins using the Olink ProSeek CVD array in 3,394 128 
European subjects with at least 3 established CVD risk factors. The majority of these proteins are 129 
strong candidates for involvement in atherosclerosis, plaque rupture or thrombosis and many are 130 
upregulated in CVD patients compared to controls or predict future risk of CVD events, such as CAD. 131 
The aims of the study were to i) identify genetic loci for circulating plasma proteins that have 132 
previously been connected with CVD, ii) explore the mechanisms underpinning novel loci by 133 
integrating genetics with other biological information and iii) apply the tools to test causality in CAD.  134 
Results 135 
Of 83 proteins selected for known involvement in vascular disease and inflammation [13] 136 
(supplementary table S3), we observed 79 SNP-trait associations, consisting of 78 SNPs and their 137 
associations with 56 proteins (figure 1 and table 1). Of the 79 associations, 41 were cis effects, where 138 
the index-SNP is within 500 kb of the gene encoding the measured plasma protein. The functional 139 
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effect at each of these 41 loci is likely to be a direct effect either on the sequence of the plasma protein 140 
or on regulatory variants proximal to the encoding gene. Additionally, we identified 38 trans effects, 141 
all acting over distances more than 100 MB or at different chromosomes from the gene encoding the 142 
associated protein.  Both cis and trans findings represent new understanding of the direct regulation of 143 
candidate CVD proteins, with trans findings additionally providing an opportunity for new insight 144 
into regulatory pathways.  145 
We could replicate all but 6 of the pQTLs at nominal significance (P<0.05) measured in three 146 
independent cohorts (n=2,639). All but 16 of the measureable pQTLs were found to be reproducible at 147 
P<0.0007 (Bonferroni corrected value). An additional 8 pQTLs were not measured in the replication 148 
cohorts. All 79 SNP-trait associations are reported in table 1 along with indication of replication 149 
status. Detailed replication statistics is available in supplementary table S1. 150 
Protein quantitative trait loci acting in trans 151 
For each of the reported trans associations, we evaluated the most likely cis-gene intermediary, and 152 
investigated pathways in the direction of the plasma protein (table 2). Analysis of coding proxies 153 
revealed that 10 trans loci had missense mutations in linkage disequilibrium (LD) with the index-154 
SNPs, providing an obvious explanatory model for the mechanism of action.  155 
The analysis of cis-eQTLs in 11 large eQTL data sets provided evidence for an additional 13 mediator 156 
cis-genes. Some of the findings were remarkably independent of tissue and cell-type, and showed 157 
concordant results in several of the 11 eQTL datasets under analysis, as indicated in table 2. At each 158 
locus with significant cis-eQTL association, we additionally investigated neighbouring eQTL and 159 
pQTL effects as LocusZoom plots (supplementary figure S2). In some cases, like rs4810479/KITLG, 160 
the index-SNP shows both the strongest association with KITLG and the strongest cis-gene 161 
association (PLTP in liver). However, cases also exist, like rs200373/CTSL1, where stronger eQTL 162 
effects for the candidate cis-gene intermediary exists from other SNPs, with low LD between the 163 
SNPs precluding straightforward interpretation. Further studies would be required to address this 164 
issue. 165 
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In pathway analysis using the String-database of protein interactions, an additional 6 trans-genes were 166 
highlighted as possible mediator genes through functional protein connections. The criterion in this 167 
analysis was that less than 5% of randomly re-wired networks had shorter distance, dictating simply 168 
that connections of length 1 from a cis-gene to the trait gene should be selected. Additionally, a more 169 
sophisticated weighted network analysis was performed where each path through the network was 170 
weighted by the strength of the (trans) eQTL of the index-SNP. The eQTL values were calculated 171 
using a large collection of eQTL databases with tissue and cells relevant to cardiovascular disease. 172 
Like in the unweighted network analysis permutation was used to determine significance threshold. 173 
Through this weighted network analysis approach we discovered 11 additional mediator candidates, 174 
examples being the rs61598054 -> FOXO3 -> AKT1 -> and the rs693918 -> XDH -> TLR4 -> IL18 175 
that are illustrated in figure 2A and 2B.  176 
Systematic literature mining suggested an additional 5 possible mediators. Co-occurrence in scientific 177 
abstracts can indicate real biological relationships that may be missing from the String network.  178 
Interestingly, across all trans-pQTL loci, the largest number of abstract co-occurrences was 626 for 179 
the receptor-ligand pair encoded by TNFSF11 and TNFRSF11B, a protein-protein interaction also 180 
reported in String-db. 181 
The results of these five mediator-gene assigning approaches are summarised in table 2. While 182 
examples given above provide relatively clear indications of mechanism, more challenging cases do 183 
exist: the IL6-SNP rs10947260 for example gives evidence pointed at three candidate cis-mediator 184 
genes: NOTCH4, AGER, and ATF6B. NOTCH4 and ATF6B were identified as containing FDR5% 185 
significant pathways to the destination IL6 (figure 2D). AGER was mentioned together with IL6 in 64 186 
separate publications.  AGER and ATF6B exhibit weak cis-eQTL effects with the index-SNP.  All 187 
were found at some distance from the index-SNP (>180 kb). Further experimentation is required to 188 
establish the main mechanism in this case. 189 
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Pleiotropy of loci affecting protein levels 190 
Inspection of potential pleiotropic effects of index SNPs on measured protein traits as described in 191 
Methods revealed 6 distinct candidate loci (supplemental figure S1). The ABO locus affecting THBD, 192 
TEK, F3, PECAM1, and SELE in our dataset and the FUT2 locus affecting MMP10, F3, and LGALS3 193 
are well known for their pleiotropic effects [14]. Furthermore, all SNPs affecting BNP levels seem to 194 
impact NPPB levels as well indicating their effect on steps before cleavage of the precursor protein. 195 
NTproBNP is a prohormone with an inactive N-terminal part that is cleaved to produce the active 196 
BNP. However, because of its half-life NTproBNP is typically used as a prognostic biomarker. A 197 
locus within the ZFPM2 gene seems to have a strong effect on PDGFB, DDK1, and, to a lesser extent, 198 
on VEGFA. Finally, the cluster of cis-acting variants in the MMP1, MMP3, and MMP12 loci are not 199 
specific to only one of the proteins but seem to impact all three of the metalloproteinases in this 200 
genomic region. 201 
Additionally, we investigated the known associations of the index-SNPs with a broad range of other 202 
phenotypes, as previously reported in literature (supplemental table S2).. 203 
Associations between plasma proteins and cardiovascular risk 204 
To assess a potential causal involvement of each protein in CAD, we calculated genetic risk scores 205 
from the publically available CARDIoGRAMplusC4D GWAS data with the aim to construct a more 206 
powerful genetic instrument for those markers for which there were multiple SNPs. First, a systematic 207 
look-up of all reported pQTL-SNPs was performed to test for association with CAD (table 3). Then, 208 
we further explored proteins with multiple independent loci by calculating pooled SNP scores per 209 
protein, thus creating more powerful instruments to analyze the causality for proteins with multiple 210 
SNPs.  Results show that of the SNPs contributing to the concentrations of proteins (Table 1), eight 211 
were also significantly associated with risk of CAD (Table 3). These findings suggest a causal role for 212 
these proteins, and whilst the cis IL6R finding confirms previous observations [15], the other 213 
observations extend our knowledge of important factors in CVD. Results from pooled-scores include 214 
highlights such as the multi-SNP support of LGALS3 and the contradiction of CHI3L1 having a 215 
CAD-associated trans-effect but no CAD-association in the cis-loci.  216 
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Discussion 217 
In this study, we identified 79 pQTLs by measuring 83 plasma proteins of cardiovascular interest in a 218 
cohort of 3,394 subjects with multiple risk CVD risk factors, which may increase the power to detect 219 
genetic variants associated with CAD-associated proteins. The study provided novel insights into 57 220 
of the plasma proteins under investigation, including cis- and trans genetic regulation and effects of 221 
long-distance regulation networks and tentative evidence for causal involvement in CVD.To the best 222 
of our knowledge only a few of the findings were previously known; however reassuringly these 223 
replicated as expected: IL18/rs75649625 and rs4129267/IL6R [16], as well as AGER/sRAGE, CD40 224 
and LGALS3 cis associations [14,17,18] and the rs8176741/TEK trans association [19], and the 225 
rs635634/SELE [20] 226 
Insights into specific trans-effects 227 
A proteomics GWA study provides an interesting opportunity for the study of trans-regulatory effects, 228 
because the trait is a well-defined biological entity.  In some cases, the trans-pQTL investigating 229 
methods in table 2 converged on a very plausible candidate gene. For example, at the CCL4-230 
rs62625034 locus the effector transcript is probably the CCR5 gene, while at the TNFSF11-rs7813952 231 
locus the effector transcript is likely the TNFRSF11B gene, two examples of known ligand-receptor 232 
pairs. Another example is the IL27-rs4905 variant, which sits within the EBI3 gene. The IL27 and 233 
EBI3 genes encode the two subunits of the IL27 cytokine complex.   234 
The effector transcript at the KITLG-rs4810479 locus may be MMP9, which encodes a 235 
metalloproteinase that cleaves the KITLG gene product, a membrane-bound stem cell factor [21].  236 
Thus this trans pQTL may represent an example of genetic regulation via post-translational 237 
modification. 238 
At a few loci, we found multiple lines of evidence suggesting different mediator genes at the same 239 
locus. This is not biologically impossible, nor is it uncommon in literature [22], but it does require 240 
more careful analysis. The challenge is illustrated by the IL6-SNP rs10947260, for which separate 241 
lines of evidence pointed to three candidate cis-mediator genes. As shown in figure 2D, a criticism 242 
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against concluding on the importance of a pathway to IL6 through the CCND1 gene is that NOTCH4 243 
has many neighbours in the String-network, thereby increasing the risk of a spurious discovery.  244 
While these examples seem specific, they illustrate challenges that have major consequences for the 245 
general interpretation of any genetic association results. Analyses such as these have driven the 246 
development of popular risk-gene assignment tools (e.g. [23]). Our findings illustrate the increased 247 
power of knowing a certain pathway destination through the use of pQTL. 248 
 249 
Insights into potential causal involvement of the plasma proteins in CVD 250 
The study provided an important opportunity to systematically test each of the plasma proteins for a 251 
potential causal role in CVD by investigating whether identified pQTLs also were associated with 252 
CAD risk. If an instrumental variable, e.g. a SNP or a set of SNPs, exclusively affects one factor, and 253 
also affects an overall phenotype, such as disease risk – then it may be deduced that the protein is 254 
causally involved in the development of this disease. According to this principle, eight proteins 255 
(PECAM1, SELE, F3, IL6R, CHI3L1, LGALS3, MMP12, and PDGFB) showed evidence of 256 
potentially causal involvement in CAD. The connection between IL6R and CAD has already been 257 
described [15], and several drug trials are underway to test whether an ILR6-inhibitor (tocilizumab) is 258 
effective in treatment of CAD (clinicaltrials.org). In light of this, the remaining proteins could be of 259 
interest as therapeutic targets. 260 
There are some important limitations to the approach, as compared to a formal MR. A formal MR 261 
study requires that the genetic instrument is specific, is not in LD with other functional variants, and 262 
that there are no hidden population strata [24]. There is no reason to suspect that the second and third 263 
requirements were violated; the study was based on high-resolution imputation of cohorts that were 264 
ethnically homogeneous. Importantly, the specificity requirement was not always satisfied, weakening 265 
the findings for some proteins. This includes all the trans associations, as well as proteins for which 266 
pleiotropy was detected (supplemental figure S1 and table S2). In addition, association between 267 
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plasma protein concentrations per se and future CVD risk has not been carefully investigated for the 268 
majority of proteins included in the present study.  269 
These limitations leave LGALS3, MMP12 and PDGFB as candidates for having a causal effect on 270 
CAD. Of the three SNPs affecting levels of LGALS3, rs1169306, rs7928577 and rs33988101 in trans, 271 
only the first two also contribute to CAD risk, resulting in a pooled CAD association P-value of 272 
P=1.46e-4. For MMP12 and PDGFB, the results are based on single SNPs showing associations with 273 
protein levels. Of the three, only MMP12 is a cis effect thereby strengthening the case for it being a 274 
specific MR instrument. These limitations notwithstanding, the map of pQTLs presented here, and in 275 
particular those acting in cis, should provide the means to systematically assess potential causal roles 276 
of these biomarkers in other common complex diseases. Additionally we highlight the online resource 277 
found at www.olink-improve.com where the data pQTL can be browsed in greater detail. This may in 278 
turn help to prioritise drug targets for development of disease-modifying therapies.  279 
Conclusion 280 
In conclusion, the main contributions of this paper are: i) identification of 79 pQTLs regulating 281 
important circulating cardiovascular plasma proteins, ii) novel evidence of the regulatory mechanisms 282 
underpinning at least half of these novel loci and iii) evidence of potential causal roles in CAD 283 
development for several plasma proteins. We believe that these three principal findings provide a 284 
strong contribution to the field of cardiovascular biomarkers and beyond. 285 
 286 
Materials and Methods 287 
The IMPROVE study 288 
The IMPROVE study is a multicentre, observational study, which recruited 3,711 men and women 289 
aged between 55 to 79 years with at least three cardiovascular risk factors but without symptoms of 290 
CVD (previously described [25]). Serum and plasma from the study participants were collected at 291 
baseline, dispensed in polypropylene tubes and frozen at –80o C prior to shipment for centralized 292 
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biochemical analyses and biobanking at the Karolinska Institutet in Stockholm, Sweden. The study 293 
was approved by the ethics committees of the 7 centers of the discovery cohort [25] and by the 294 
Uppsala University ethics committee for the replication cohorts [26,27]. All participants gave written 295 
informed consent, and the study was conducted in accordance with the declaration of Helsinki. 296 
Genotyping, quality control and imputation 297 
DNA genotyping in the IMPROVE study was performed using the Illumina CardioMetabochip and 298 
Immunochip arrays. The combined SNP genotyping data from both platforms were merged and 299 
subjected to the following quality control (QC) using PLINK 1.7: SNPs were excluded for probe to 300 
genome mismatch, incorrect assignment of allelic variants in the array design, failed Hardy-Weinberg 301 
Equilibrium test at 1x10-6, call rate <95 % or failed Illumina genotype calling QC. Samples were 302 
excluded if they showed evidence of gender mismatch, abnormal inbreeding coefficient, failed cryptic 303 
relatedness test or had an overall sample call rate <95 %. After quality control, a total number of 304 
3,394 subjects remained for analysis. Imputation was performed with IMPUTE 2.0 using the 1000 305 
genomes version 5 as reference panel. The pre-imputation data set contained 244,814 SNPs and the 306 
post-imputation data set contained 5,270,624 SNPs 307 
Plasma protein determinations and quality control 308 
In total, there were 3,394 IMPROVE participants for whom quality controlled genotype information 309 
and plasma samples were available. Plasma concentrations were measured in baseline EDTA plasma 310 
samples using the ProSeek CVD array I (Olink Biosciences, Uppsala, Sweden), according to the 311 
standard protocol. The ProSeek method is based on the highly sensitive and specific proximity 312 
extension assay (PEA), which involves the binding of distinct polyclonal oligonucleotide-labelled 313 
antibodies to the target protein followed by quantification by real-time quantitative PCR [13]. In 314 
addition to the controls provided by Olink Biosciences, a pooled plasma control was included in all 315 
plates to enable further quality control (QC) such as calculation of variation coefficients. Prior to 316 
statistical analyses, we excluded individual assays with more than 20 % of samples below the lower 317 
detection limit and those with final inter-plate coefficients of variation above 25 %. After QC, a total 318 
number of 83 proteins out of the 92 remained for analysis. The native scale of Olink protein 319 
14 
 
measurements is log(2) but additional log(10) transformations were performed to ensure normally 320 
distributed variables. Validation of the OLINK method has been conducted [13], and the method has 321 
been used to validate previous findings obtained with established protein quantification methods 322 
[26,28]. 323 
Genome-wide quantitative trait locus discovery 324 
Plasma protein readings were log10 transformed prior to analyses. Standardized residuals for each of 325 
the 83 plasma proteins were calculated using a linear model adjusting for age, sex, recruitment centre, 326 
protein analysis batch, smoking, diabetes and hypertension at baseline. To merge loci in table 1 and 327 
table S1, signals with R2 higher than 0.1 and distance within 250 KB were omitted, retaining only the 328 
strongest signal in each block, referred to as the index SNP.  The standardized residuals were used in 329 
a Wald-test in PLINK 1.9 to test association between genetic data and each plasma protein, using a 330 
significance threshold of P < 5e-8. All summary statistics can be downloaded at www.olink-331 
improve.com [review pass-mail: rev3@ki.se]. 332 
Narrow-sense heritability for all proteins was calculated using Genome-Wide Complex Trait Analysis 333 
[29]. A genetic relationship matrix was calculated using all imputed autosomal SNPs with imputation 334 
scores above R2=0.9, less than 1 % missingness and allele frequency above 5 %, in total 2,617,215 335 
SNPs. The variants were hard called before estimating the phenotypic variance explained by all 336 
autosomal SNPs using the restricted maximum likelihood analysis (REML). 337 
Replication of pQTL effects 338 
Replication studies of all pQTLs were performed in three community-based cohorts in which Olink 339 
array protein data and genotypes were available. These cohorts were the NSPHS [27], the Prospective 340 
Investigation of the Vasculature in Uppsala Seniors (PIVUS) and the Uppsala Longitudinal Study of 341 
Adult Men (ULSAM) [26], consisting of samples from 976, 933 and 730 participants, respectively. 342 
Statistics were calculated according to additive association models, and findings were matched either 343 
directly on imputed SNP-id (96% of cases) or using a proxy with R2 > 0.8 linkage disequilibrium. 344 
Replication P-values were calculated using the METAL meta-analysis software (version 2011-03-25). 345 
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Expression quantitative trait analysis 346 
For each index-SNP, cis- and trans-eQTL data were calculated from the following sources: aorta 347 
intima-media, aorta adventitia, liver, mammary artery, and heart from the ASAP study [30], 348 
monocytes and B-cells from the Fairfax et al study [31], and monocytes stimulated with LPS-2h, LPS-349 
24h and interferon-2h from another Fairfax et al study [32]. Each of these 11 data sets had information 350 
from gene expression microarrays and genotyping microarrays as described in the respective 351 
references. The mean sample size was 223 with a range of 89-367. Data from genotyping microarrays 352 
were imputed using the MACH 1.0 algorithm with 1000 genomes CEU data as reference (mean rsq 353 
quality score 0.89) [33]. The strength of eQTL association was calculated using a linear additive 354 
model between log2-transformed expression value and numerically encoded genotype data. For cis-355 
eQTL associations, un-corrected p-values from cis-eQTL were reported if the association was 356 
stronger than P < 0.0005 (corresponding to a false discovery rate (FDR) <5%). For all significant cis-357 
eQTL associations, locusZoom plots were generated showing regional effect differences between 358 
eQTL and pQTL studies [34]. 359 
Network analysis 360 
The network analysis was performed based on the String database network (version 10) [35], using all 361 
edges with a confidence score above 400. For all genes within 0.5 MB of an effect-SNP (“cis-genes”), 362 
the shortest path length was calculated between the cis-gene and the gene encoding the measured 363 
protein biomarker (“trait-gene”) using the igraph package in R (version 1.0.1). This was done both 364 
with an unweighted version of the Stringdb-network as well as with a weighted version, wherein each 365 
gene along the path was weighted by the trans-eQTL strength calculated from the effect-SNP (scored 366 
as 1, except if PeQTL < 0.05 which gave score 0.8, and if PeQTL < 0.005, which gave score 0.6).   367 
For both weighted and unweighted networks, significance of a path was calculated as the fraction of 368 
1000 randomly permuted networks that obtained a shorter path length than the one tested. Random 369 
networks were generated using permutation of the original scores and random rewiring of the network 370 
using the igraph rewire function, as detailed in code repository http://github.com/lassefolkersen/olink-371 
improve. Given our data, only paths of length 1, i.e. direct links in String-db, were significant at a 372 
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0.05 level in the unweighted case. For the weighted case, only paths of length 2 with an intermediate 373 
trans-eQTL gene reached significance. Paths were subsequently checked for biological plausibility. 374 
Literature analysis 375 
To support the assignment of potential causal genes in pQTLs, we mined the literature for topical co-376 
occurrences of each gene in a pQTL (defined by a 500kb window) with its associated protein. The 377 
Pfizer-internal LitMS tool can provide such matches based on all PubMed abstracts, a large synonym 378 
dictionary and manually curated rules that limit findings to more relevant articles, e.g. those in which 379 
gene and protein occur in the abstract’s title [36]. The system outputs the number of co-occurrences 380 
and underlying article references for each gene-protein input pair. We then reviewed the literature 381 
findings to assign the most plausible causal genes where possible. 382 
Pleiotropy 383 
To understand the specificity of all reported index-SNPs we inspected all index SNPs that had at least 384 
2 associations with distinct proteins at P<0.05 / (83* 79) =7.7e‐6. This cutoff reflects a conservative 385 
approach to the multiple testing burden for all identified index SNPs (79) with all tested protein traits 386 
(83). The resulting association matrix was then clustered and visualized based on the negative log10 387 
of the p-values of association. For the clustering, we used a complete-linkage hierarchical clustering 388 
approach based on correlation coefficients as a metric. In addition, index-SNPs were investigated for 389 
other associations in publically available GWAS databases. 390 
Calculation of genetic risk scores 391 
To assess the effect on disease, the publicly available CARDIoGRAMplusC4D 1000G imputed data 392 
was interrogated [37]. The goal was to perform in silico analysis for every SNP that showed 393 
significant associations with any of the measured traits. For traits that had multiple associated SNPs, 394 
pooled scores per affected protein were calculated using the R-package gtx version 0.0.8. Specifically 395 
for the pooled risk scores, the alleles of each protein were encoded so that the coded allele was 396 
increasing CAD risk regardless of its protein concentration effect. This ensured that pooled effect 397 
sizes reflected uniform directionality on CAD risk. 398 
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Tables 571 
Table 1 572 
SNP id Trait  -log(P)  SNP id Trait  -log(P) 
Cis-acting loci   Trans-acting loci 
rs1580006‡ ADM 14.69  rs184243355* CCL3 7.65 
rs2070600‡ AGER (RAGE) 9.52  rs73062378 CCL4 12.35 
rs549596* BNP 13.76  rs62625034 CCL4 40.51 
rs2188974 CCL3 17.31  rs28601761 CHI3L1 8.3 
rs6607368 CCL4 30.2  rs200373 CTSL1 8.37 
rs1569723 CD40 48.52  rs6993770 DKK1 8.79 
rs2153101 CHI3L1 107.13  rs495828 F3 9.34 
rs17610659 CSF1 9.19  rs200433550* F3 9.25 
rs35285321 CSTB 42.93  rs1260326 
FST 
(Follistatin) 8.69 
rs11169323
5 CTSD 25.69  rs4672375 GAL 10.15 
rs670211 CX3CL1 11.13  rs76519098† GDF15 9.95 
rs74544699 CXCL1 11.88  rs693918 IL18 10.62 
rs35186877 CXCL16 8.76  rs7599125‡ IL18 7.95 
rs72650832 CXCL6 41.21  rs35166255 IL1RL1 8.93 
rs982764 FAS 11.7  rs11599750 IL27 9.85 
rs3195944 GDF15 7.65  rs10947260† IL6 9.74 
rs6555820 HAVCR1 86.89  rs4810479 KITLG 10.35 
rs13236526 HSPB1 16.96  rs7928577 LGALS3 8.67 
rs13987964
0* IL16 61.53  rs1169306‡ LGALS3 8.19 
rs75649625 IL18 20.84  rs33988101‡ LGALS3 8.45 
rs1420101 IL1RL1 131.69  rs12570111† MMP1 7.33 
rs4905 IL27 79.93  rs492602 MMP10 8.11 
rs4129267 IL6R 264.67  rs12469459 MUC16 44.15 
rs62115757 KLK11 61.91  rs61598054* NGF 7.42 
rs11667946 KLK6 14.47  rs75416436† NGF 7.38 
rs9323280 LGALS3 61.25  rs6557662* NPPB 7.83 
rs471994 MMP1 34.63  rs140000161 PAPPA 9.84 
rs17368659 MMP12 96.26  rs16873402‡ PDGFB 7.62 
rs7946057 MMP3 107.92  rs635634 PECAM1 44.72 
rs56378716 MPO 8.73  rs117538444† PGF 8.18 
rs35207557* NPPB 24.59  rs635634 
SELE (E-
selectin) 
219.0
2 
rs880949‡ PGF 7.8  rs8176741 TEK 49.06 
rs11666116
3 
REN 
(Renin) 7.99  rs8176693 THBD 9.95 
rs1969539 SPON1 21.82  rs241771‡ TNFRSF11B 9.22 
rs79250370 TEK (TIE2) 12.71  rs142552223 
TNFSF11 
(TRANCE) 16.47 
rs3176123 THBD 23.64  rs7813952 
TNFSF11 
(TRANCE) 15.67 
23 
 
rs6469811 
TNFRSF11B 
(Osteprote
gerin) 
10.54  rs35538083† XPNPEP2 7.51 
rs76769120‡ TNFRSF1B (TRAIL) 10.87  rs11150189‡ XPNPEP2 13.16 
rs344560 TNFSF14 17.53     
rs2050011* XPNPEP2 67.62         
rs2271025 AGRP 8.63     
 573 
Overview of pQTL associations  574 
More commonly used non-systematic names indicated in parenthesis for some proteins. * pQTL that 575 
was not measured in replication cohorts, † pQTL that was measured in replication cohorts, but did not 576 
replicate at P<0.05, ‡ pQTL that did not replicate at Bonferroni corrected value of P<0.0007. A more 577 
detailed version of this table is found as supplemental table S1. 578 
 579 
 580 
 581 
 582 
 583 
 584 
 585 
  586 
24 
 
Table 2 587 
trait-gene SNP cis-gene Distan
ce (kb) 
Dist-
rank 
Coding-proxy Cis-eQTL Un-weighted-
pathway 
eQTL-
weighted-
pathway 
Literatur
e-score 
CCL4 rs62625034 CCR5 0 1 rs62625034 (R2=1)    59 
CTSL1 rs200373 IFI30 0 1  Monocytes+LPS 
(P=2.6e-05), 
Monocytes+IFN 
(P=1e-04) 
   
  MAST3 24 5 rs8108738 
(R2=0.64) 
    
F3 rs495828 SURF6 43 2  Monocytes (P=2.9e-
05), B-cells (P=3.4e-
05) 
   
  MED22 53 3    Via PPARD 
(P=0.00321) 
 
FST rs1260326 GCKR 0 1 rs1260326 (R2=1)     
  KRTCAP3 62 4  B-cells (P=3.4e-08)    
GDF15 rs76519098 MAPK8 283 4   Yes Yes, short  
IL18 rs693918 XDH -231 3    Via TLR4 
(P=0.00085) 
 
IL18 rs7599125 LTBP1 -311 3    Via TGFB2 
(P=0.00321) 
 
  NLRC4 -371 5   Yes Yes, short  
IL1RL1 rs35166255 TIRAP 137 4   Yes Yes, short  
  RPUSD4 -220 8  Monocytes+IFN 
(P=0.00034) 
   
IL27** rs11599750 CWF19L1 187 6  4 eQTL-sets show 
cis-eQTL effect** 
   
IL6* rs10947260 BTNL2 0 1 rs60263670 (R2=1)     
  NOTCH4 -181 6    Via CCND1 
(P=0.00427) 
 
  AGER -221 9     64 
  ATF6B -277 18    Via ATF3 
(P=0.00349) 
 
KITLG rs4810479 PLTP -4 1  Liver (P=4.2e-09), 
B-cells (P=4.3e-07) 
   
  PCIF1 -18 3  Monocytes+IFN 
(P=5.4e-05) 
   
  ACOT8 -59 9  Monocytes+IFN 
(P=0.00021) 
   
  MMP9 -92 12   Yes Yes, short  
LGALS3 rs7928577 TIRAP 63 3    Via IL6 
(P=0.000463) 
 
  CDON -295 9    Via CTNNB1 
(P=0.00494) 
 
LGALS3 rs1169306 HNF1A 0 1 rs2464196 
(R2=0.71) 
    
  C12orf43 3 2  5 eQTL-sets show 
cis-eQTL effect 
   
LGALS3 rs33988101 RASIP1 6 2 rs2287922 
(R2=0.88) 
    
  FUT2 9 3 rs602662 
(R2=0.68) 
    
  FGF21 -41 6    Via EGFR 
(P=0.000853) 
 
  BCAT2 80 10    Via GAPDH 
(P=0.000584) 
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MMP10 rs492602 FUT2 0 1 rs601338 
(R2=0.99) 
    
  RASIP1 17 3 rs2287922 
(R2=0.68) 
    
  PPP1R15A -169 18    Via GADD45A 
(P=0.0045) 
  BAX -252 26    Via TNF 
(P=0.00461) 
 
MUC16 rs12469459 GAL3ST2 0 1 rs12469459 (R2=1)     
  D2HGDH 8 2  Monocytes (P=9.6e-
06) 
   
NGF rs61598054 FOXO3 -70 2    Via AKT1 
(P=0.00376) 
 
PAPPA rs140000161 PRG2 0 1  Monocytes+IFN 
(P=5.4e-06) 
Yes Yes, short  
PECAM1 rs635634 SURF6 43 2  B-cells (P=1.7e-05), 
Monocytes (P=3.3e-
05) 
   
SELE rs635634 SURF6 43 2  B-cells (P=1.7e-05), 
Monocytes (P=3.3e-
05) 
   
  MED22 53 3    Via PPARD 
(P=0.00277) 
 
TEK rs8176741 ABO 0 1 rs8176747 
(R2=0.98) 
    
  MED22 76 5    Via ALB 
(P=0.00266) 
 
  RPL7A -84 6    Via UBC 
(P=0.000421) 
 
  GBGT1 -92 9    Via ALB 
(P=0.00266) 
 
THBD rs8176693 ABO 0 1 rs8176746 (R2=1)     
TNFSF11 rs7813952 TNFRSF11
B 
-159 3   Yes Yes, short 626 
 588 
Systematic analysis of potential mechanisms behind trans-pQTL associations.  589 
For each of 41 SNPs that had an effect in trans, cis-genes within 500 kb were analysed using 5 590 
different methods for evaluation of mediator cis-gene: 1) presence of non-synonymous coding SNP in 591 
LD with index SNP at R2>0.65, 2) presence of FDR5% cis-eQTL effect, 3) presence of significant 592 
pathway to trait-gene shorter than 95% of randomly permuted pathways, 4) presence of eQTL-593 
weighted pathway to trait-gene shorter than 95% of randomly permuted pathways and/or 5) literature 594 
matching score above 50. A total of 1618 SNP-cis-gene pairs were considered, but only pairs that 595 
satisfied at least one of the tests are shown. * Shown in figure 1B. ** Shown in figure 1A. 596 
 597 
 598 
 599 
 600 
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Table 3 601 
SNP Trait-
protein 
Cis / 
trans 
Pprotein βCAD PCAD βCAD-pool PCAD-pool 
rs635634 PECAM1 trans 1.9E-45 0.08 4.47E-11   
rs635634 SELE trans 9.6E-220 0.08 4.47E-11   
rs495828 F3 trans 4.5E-10 0.07 1.29E-10   
rs4129267 IL6R cis 2.1E-265 0.05 2.21E-07   
rs28601761 CHI3L1 trans 5.1E-09 0.05 1.00E-06 0.03 2.3E-05 
rs1169306 LGALS3 trans 6.5E-09 0.03 5.69E-04 0.02 5.9E-05 
rs7928577 LGALS3 trans 2.2E-09 0.06 1.28E-03 0.02 5.9E-05 
rs17368659 MMP12 cis 5.5E-97 0.05 1.39E-03   
rs16873402 PDGFB trans 2.4E-08 0.03 1.47E-03   
rs6993770 DKK1 trans 1.6E-09 0.03 6.90E-03   
rs880949 PGF cis 1.6E-08 0.02 2.00E-02 0.02 2.0E-02 
rs17610659 CSF1 cis 6.5E-10 0.02 2.25E-02   
rs112579976 CCL4 trans 2.5E-13 0.05 3.03E-02   
rs9323280 LGALS3 cis 5.6e-62 0.02 3.20E-01 0.02 5.9E-05 
rs2153101 CHI3L1 cis 7.5E-108 0.01 4.68E-01 0.03 2.3E-05 
rs33988101 LGALS3 trans 3.6E-09 0.01 5.16E-01 0.02 5.9E-05 
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rs117538444 PGF trans 6.5E-09 0.01 7.64E-01 0.02 2.0E-02 
Association between pQTLs and coronary artery disease (CAD) risk.  602 
Each SNP from supplemental table S1 was investigated in the CARDIoGRAMplusC4D data, and the 603 
P-values for the pQTL and CAD risk were extracted. An additional pooled analysis was performed in 604 
cases where one plasma protein had multiple pQTLs,.  The table shows all pQTLs for which either a 605 
single-SNP or pooled CAD association had a P<0.05. P-values highlighted in italics indicate that the 606 
association was also significant after correction for multiple testing. 607 
608 
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Figure Legends 609 
Figure 1 610 
Genome-wide association strength of all measured plasma proteins.  611 
The extent of each stack indicates the negative log P of association between the plasma protein and 612 
SNPs. Stacks with black dots and black text labels indicate cis-associations. Stacks with hollow 613 
circles and grey text labels indicate trans-associations; their targets are indicated with central colour 614 
coded lines. Consequently, plasma proteins having both cis- and trans-effects can be identified as 615 
those with a black dot stack as well as connecting lines from hollow dots, e.g. XPNPEP2 or CCL4. 616 
Fully drawn circle shows P=5e-8. Dashed circle shows 1e-15. A detailed table of the genome-wide 617 
significant associations in this figure is available as supplemental table S1. 618 
 619 
Figure 2 620 
String-database network connections between proximal cis-gene and target plasma protein.  621 
All short String paths that connect proximal cis-genes with the target plasma protein are shown. The 622 
colour intensity of each gene shows the eQTL association-strength with the index-SNP. The nodes 623 
highlighted with bold border show paths that satisfy P<0.05 in network permutation analysis. A) the 624 
rs61598054-SNP is harboured in an intron of the LACE1 gene, but have no paths to the target gene 625 
NGF and a more likely mechanism is therefore FOXO3 -> AKT1 -> NGF, which involves a 626 
rs61598054-trans-eQTL effect on AKT1. In permutation analysis of re-wired networks this is stronger 627 
than 95% of random networks. B) Similarly for rs693918, while located between SRD5A2 and 628 
MEMO1, the path XDH -> TLR4 -> IL18 is a more likely mechanistic path, supported by eQTL 629 
effects on both XDH and TLR4. C)  The rs61598054-AKT1 trans-eQTL from panel A in 235 IFN-630 
stimulated monocytes and the rs10947260-ATF3 trans-eQTL from panel D in 89 mammary artery 631 
samples. D) Although rs10947260 is found in an intron of BTNL2, no obvious path exists between 632 
BTNL2 and IL6. However, both ATF6B -> ATF3 -> IL6 and NOTCH4 -> CCND1 -> IL6 are 633 
significant. DNA-strands are not to scale. 634 
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SUPPLEMENTAL	MATERIAL	
Figure	S1	
Potential pleiotropy between genome‐wide significant SNPs and measured trait proteins. This figure shows all lead SNPs that have at least 2 
associations with distinct proteins at P<0.05 / (83* 79) =7.7e‐6. This cutoff reflects a conservative approach to the multiple testing burden for all 
identified lead SNPs (79) with all tested protein traits (83). Protein traits are not displayed if they have no associations with the selected SNPs at 
the defined threshold. Red colour indicates the main effect as reported in table S1. Grey‐scale colours indicate the effect strength on a –log10(P) 
scale as indicated. 
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SNP  Position 
(chr:MB) 
Trait  Dist
(kb) 
Likely 
mediator 
gene 
Disco‐
very P 
Disco‐
very Beta 
A1/A2 A1 
freq 
INFO  Protein Name Replication 
P 
Combined 
P 
Directions 
rs2153101  chr1:203.2  CHI3L1  ‐12 CHI3L1 7E‐108 ‐0.62 A/T 0.21 1.05  Chitinase‐3‐like protein 1 7.01e‐136 1.8e‐236 ‐‐‐
rs635634  chr9:136.2  SELE  trans SURF6 1E‐219 ‐0.86 T/C 0.22 0.99  E‐selectin 8.1e‐133 <1e‐256 ‐‐‐
rs1420101  chr2:103  IL1RL1 (ST2)  0 IL1RL1 2E‐132 0.58 C/T 0.63 1.03  Interleukin‐1 receptor‐like 1 5.06e‐125 5.86e‐254 +++
rs72650832  chr4:74.7  CXCL6  ‐29 CXCL6 6.2E‐42 ‐0.53 T/C 0.65 0.41  C‐X‐C motif chemokine 6 8.79e‐104 3.12e‐130 ‐‐‐
rs635634  chr9:136.2  PECAM1  trans 1.9E‐45 ‐0.41 T/C 0.22 0.99  Platelet endothelial cell adhesion 
molecule 
3.27e‐90 6.91e‐125 ‐‐‐
rs1569723  chr20:44.7  CD40  ‐5 CD40 3E‐49 ‐0.39 C/A 0.28 1.00  Tumor necrosis factor receptor 
superfamily member 5 
1.156e‐79 1.81e‐121 ‐‐‐
rs17368659  chr11:102.7  MMP12  0 MMP12 5.5E‐97 0.82 G/T 0.85 0.70  Macrophage metalloelastase 2.15e‐76 2.84e‐171 +++
rs6555820  chr5:156.5  HAVCR1 (TIM)  0 HAVCR1 1.3E‐87 0.46 C/A 0.52 1.03  Hepatitis A virus cellular receptor1 8.443e‐60 1.76e‐145 +++
rs4129267  chr1:154.4  IL6R (IL6RA)  0 IL6R 2E‐265 0.81 T/C 0.36 0.99  Interleukin‐6 receptor subunit 
alpha 
1.617e‐56 1.53e‐297 +‐+
rs7946057  chr11:102.7  MMP3  7 MMP3 1E‐108 0.53 A/T 0.53 0.97  Stromelysin‐1 1.41e‐53 5.21e‐160 +?+
rs471994  chr11:102.7  MMP1  ‐29 MMP1 2.3E‐35 0.32 G/A 0.65 0.97  Interstitial collagenase 9.129e‐52 2.182e‐82 +++
rs62625034  chr3:46.4  CCL4  trans CCR5 3.1E‐41 ‐0.55 G/T 0.9 0.99  C‐C motif chemokine 4 2.178e‐44 7.618e‐83 ‐‐‐
rs4905  chr19:4.2  IL27 (IL27A)  0 EBI3 1.2E‐80 ‐0.49 G/A 0.3 1.02  Interleukin‐27 subunit alpha 1.59e‐40 4.52e‐119 ‐?‐
rs9323280  chr14:56  LGALS3 (GAL3)  189 LGALS3 5.6E‐62 0.77 A/C 0.87 0.60  Galectin‐3 4.052e‐34 6.6e‐94 +++
rs12469459  chr2:242.7  MUC16 (CA125)  trans GAL3ST2 7.1E‐45 0.65 A/T 0.68 0.31  Mucin‐16 1.05e‐33 3.202e‐75 +?+
rs8176741  chr9:136.1  TEK (TIE2)  trans RALGDS 8.7E‐50 ‐0.61 G/A 0.91 1.02  Angiopoietin‐1 receptor 1.769e‐30 2.264e‐78 ‐‐‐
rs74544699  chr4:74.7  CXCL1  0 CXCL1 1.3E‐12 ‐0.45 A/G 0.95 0.78  Growth‐regulated alpha protein 5.48e‐25 1.042e‐30 ‐?‐
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rs3176123  chr20:23  THBD (TM)  0 THBD 2.3E‐24 ‐0.3 T/G 0.81 1.04  Thrombomodulin 1.441e‐23 5.828e‐46 ‐‐‐
rs982764  chr10:90.8  FAS  0 FAS 2E‐12 ‐0.18 C/T 0.32 1.04  Tumor necrosis factor receptor 
superfamily member 6 
1.06e‐21 1.792e‐28 ‐?‐
rs79250370  chr9:27.2  TEK (TIE2)  0 TEK 1.9E‐13 ‐0.58 G/A 0.94 0.44  Angiopoietin‐1 receptor 5.353e‐20 1.141e‐30 ‐‐‐
rs2188974  chr17:34.4  CCL3  1 CCL3 4.9E‐18 ‐0.31 A/G 0.81 0.75  C‐C motif chemokine 3 9.466e‐19 7.919e‐35 ‐‐‐
rs6607368  chr17:34.8  CCL4  386 CCL4 6.3E‐31 0.51 A/C 0.8 0.46  C‐C motif chemokine 4 1.78e‐18 2.081e‐47 +?+
rs111693235  chr11:1.8  CTSD  4 CTSD 2E‐26 0.35 C/G 0.71 0.65  Cathepsin D 2.1e‐17 1.071e‐41 +?+
rs4810479  chr20:44.5  KITLG (SCF)  trans MMP9 4.5E‐11 ‐0.18 T/C 0.74 1.01  Kit ligand 8.921e‐17 2.802e‐25 ‐‐‐
rs62115757  chr19:51.5  KLK11 (HK11)  4 KLK11 1.2E‐62 0.77 T/G 0.79 0.39  Kallikrein‐11 6.13e‐16 6.693e‐76 +?+
rs670211  chr16:57.4  CX3CL1  0 CX3CL1 7.4E‐12 0.18 G/A 0.41 0.84  Fractalkine 3.654e‐15 7.084e‐25 +++
rs344560  chr19:6.7  TNFSF14  0 TNFSF14 3E‐18 0.75 C/T 0.96 0.46  Tumor necrosis factor ligand 
superfamily member 14 
5.478e‐15 1.313e‐31 +‐+
rs35285321  chr21:45.2  CSTB  ‐6 CSTB 1.2E‐43 ‐0.43 A/G 0.38 0.64  Cystatin‐B 7.56e‐15 7.873e‐57 ‐‐?
rs75649625  chr11:112.1  IL18  ‐17 IL18 1.4E‐21 0.29 G/A 0.76 0.86  Interleukin‐18 3.323e‐13 4.094e‐33 +++
rs1969539  chr11:14  SPON1  0 SPON1 1.5E‐22 ‐0.25 G/A 0.5 0.89  Spondin‐1 5.531e‐13 8.121e‐34 ‐‐‐
rs693918  chr2:31.9  IL18  trans 2.4E‐11 0.19 G/A 0.55 0.72  Interleukin‐18 2.905e‐12 7.815e‐22 +++
rs1260326  chr2:27.7  FST (FS)  trans GCKR 2E‐09 0.14 T/C 0.44 1.07  Follistatin 8.217e‐11 1.863e‐18 +++
rs4672375  chr2:60.5  GAL  trans 7.1E‐11 0.17 G/A 0.58 0.90  Galanin peptides 3.79e‐10 8.019e‐19 +?+
rs116661163  chr1:204.6  REN  ‐475 REN 1E‐08 ‐0.72 C/G 0.98 0.38  Renin 4.168e‐10 4.455e‐17 ‐‐‐
rs142552223  chr3:172.2  TNFSF11 
(TRANCE) 
trans 3.4E‐17 0.81 G/A 0.97 0.58  Tumor necrosis factor ligand 
superfamily member 11 
6.042e‐10 1.636e‐25 +++
rs13236526  chr7:75.9  HSPB1 (HSP27)  0 HSPB1 1.1E‐17 0.36 A/G 0.7 0.44  Heat shock protein beta‐1 1.59e‐09 2.35e‐25 ++?
rs3195944  chr19:18.5  GDF15  ‐20 GDF15 2.2E‐08 ‐0.33 A/G 0.88 0.39  Growth differentiation factor 15 8.05e‐09 5.618e‐15 ‐?‐
rs56378716  chr17:56.4  MPO  0 MPO 1.9E‐09 ‐0.5 G/A 0.02 0.99  Myeloperoxidase 4.798e‐08 5.002e‐16 ‐‐‐
rs73062378  chr3:45.8  CCL4  trans 4.5E‐13 ‐0.29 T/C 0.81 0.61  C‐C motif chemokine 4 7.16e‐08 2.257e‐19 ‐?‐
rs140000161  chr11:57.2  PAPPA  trans 1.4E‐10 ‐0.37 A/G 0.91 0.55  Pappalysin‐1 9.1e‐08 1.27e‐16 ‐?‐
rs28601761  chr8:126.5  CHI3L1  trans 5E‐09 0.14 C/G 0.61 1.03  Chitinase‐3‐like protein 1 3.746e‐07 9.569e‐15 +++
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rs8176693  chr9:136.1  THBD (TM)  trans MED22 1.1E‐10 ‐0.27 C/T 0.91 1.03  Thrombomodulin 4.021e‐07 2.427e‐16 ‐‐‐
rs7813952  chr8:120.1  TNFSF11 
(TRANCE) 
trans TNFRSF11B 2.1E‐16 0.22 C/T 0.58 0.81  Tumor necrosis factor ligand 
superfamily member 11 
4.092e‐07 1.284e‐21 +++
rs200373  chr19:18.3  CTSL1  trans 4.3E‐09 ‐0.14 T/A 0.48 1.03  Cathepsin L1 5.46e‐07 2.116e‐14 ‐?‐
rs6993770  chr8:106.6  DKK1  trans 1.6E‐09 ‐0.17 T/A 0.27 0.99  Dickkopf‐related protein 1 8.545e‐06 7.278e‐14 ‐‐‐
rs2271025  chr16:67  AGRP  530† 2.3E‐09 ‐0.36 G/A 0.92 0.55  Agouti‐related protein 1.866e‐05 2.346e‐13 ‐‐‐
rs35186877  chr17:4.6  CXCL16  11 CXCL16 1.7E‐09 0.21 G/A 0.81 0.76  C‐X‐C motif chemokine 16 3.07e‐05 2.54e‐13 +?+
rs35166255  chr11:126.3  IL1RL1 (ST2)  trans 1.2E‐09 ‐0.46 G/A 0.96 0.68  Interleukin‐1 receptor‐like 1 3.69e‐05 2.02e‐13 ‐?‐
rs492602  chr19:49.2  MMP10  trans FUT2, 
RASIP1 
7.8E‐09 0.14 G/A 0.45 1.03  Stromelysin‐2 5.71e‐05 2.364e‐12 +++
rs11667946  chr19:51.5  KLK6  ‐1 KLK6 3.4E‐15 0.3 C/T 0.53 0.41  Kallikrein‐6 0.000116 2.909e‐18 +?+
rs7928577  chr11:126.2  LGALS3 (GAL3)  trans TIRAP 2.1E‐09 0.26 T/G 0.08 0.98  Galectin‐3 0.0001312 1.834e‐12 +++
rs495828  chr9:136.2  F3 (TF)  trans SURF6 4.6E‐10 ‐0.17 T/G 0.25 0.99  Tissue factor 0.0001693 6.249e‐13 ‐‐‐
rs17610659  chr1:110.5  CSF1  30 CSF1 6.5E‐10 0.15 T/C 0.48 0.97  Macrophage colony‐stimulating 
factor 1 
0.000228 1.202e‐12 +++
rs11599750  chr10:101.8  IL27 (IL27A)  trans CWF19L1 1.4E‐10 0.16 C/T 0.62 1.00  Interleukin‐27 subunit alpha 0.000429 2.816e‐13 +?+
rs6469811  chr8:120.1  TNFRSF11B 
(OPG) 
‐137 TNFRSF11B 2.9E‐11 ‐0.18 G/A 0.55 0.81  Osteprotegerin 0.0005594 2.52e‐13 ‐‐‐
rs76769120  chr1:12.2  TNFRSF1B 
(TRAIL/TNFR2) 
0 TNFRSF1B 1.3E‐11 0.42 G/T 0.91 0.46  Tumor necrosis factor receptor 
superfamily member 1B 
0.000869 6.649e‐14 +?+
rs11150189  chr16:79.7  XPNPEP2 
(MAMP) 
trans 6.9E‐14 0.2 A/G 0.69 0.97  Xaa‐Pro aminopeptidase 2 0.00104 3.739e‐16 ++?
rs2070600  chr6:32.2  AGER (RAGE)  0 AGER 3E‐10 ‐0.37 T/C 0.04   Advanced glycosylation end 
product‐specific receptor 
0.001181 4.749e‐12 ‐+‐
rs241771  chr17:26.6  TNFRSF11B 
(OPG) 
trans 6E‐10 ‐0.15 T/C 0.45 0.98  Osteprotegerin 0.003457 3.469e‐11 ‐‐‐
rs1169306  chr12:121.4  LGALS3 (GAL3)  trans HNF1A, 
C12orf43 
6.5E‐09 0.14 T/C 0.38 1.02  Galectin‐3 0.003868 2.847e‐10 +‐+
rs16873402  chr8:106.6  PDGFB  trans 2.4E‐08 0.15 C/T 0.71 0.94  Platelet‐derived growth factor 
subunit B 
0.005719 1.407e‐09 +++
rs7599125  chr2:32.9  IL18  trans NLRC4 1.1E‐08 ‐0.23 G/A 0.44 0.35  Interleukin‐18 0.006416 8.746e‐10 ‐‐‐
rs33988101  chr19:49.2  LGALS3 (GAL3)  trans FUT2, 
RASIP1 
3.5E‐09 0.14 T/G 0.48 1.04  Galectin‐3 0.009141 5.557e‐10 +++
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rs880949  chr14:75.4  PGF (PLGF)  6 PGF 1.6E‐08 ‐0.17 G/A 0.58 0.68  Placenta growth factor 0.01379 3.281e‐09 ‐‐‐
rs1580006  chr11:10.4  ADM (AM)  42 ADM 2E‐15 ‐0.19 A/T 0.54 1.00  Pro‐adrenomedullin 0.02987 7.124e‐14 ‐‐‐
rs10947260  chr6:32.4  IL6  trans NOTCH4, 
AGER, ATF6B 
1.8E‐10 0.25 C/T 0.1   Interleukin‐6 0.1524 6.21e‐09 +++
rs35538083  chr1:27.1  XPNPEP2 
(MAMP) 
trans PIGV 3.1E‐08 ‐0.27 T/C 0.93 0.95  Xaa‐Pro aminopeptidase 2 0.181 3.717e‐08 ‐‐?
rs75416436  chr13:42.6  NGF (BETANGF)  trans 4.2E‐08 ‐0.5 G/A 0.96 0.44  Beta‐nerve growth factor 0.286 9.912e‐08 ‐‐?
rs12570111  chr10:12.3  MMP1  trans 4.7E‐08 0.14 T/C 0.56 0.94  Interstitial collagenase 0.616 1.4e‐05 +?‐
rs76519098  chr10:49.9  GDF15  trans MAPK8 1.1E‐10 ‐0.83 C/T 0.98 0.39  Growth differentiation factor 15 0.6989 2.571e‐06 ‐‐+
rs117538444  chr15:89.9  PGF (PLGF)  trans 6.6E‐09 0.78 C/T 0.98 0.37  Placenta growth factor 0.9649 9.685e‐06 +‐+
rs549596  chr1:11.9  BNP  1 NPPB 1.7E‐14 ‐0.19 T/C 0.59 0.97  Binatriuretic peptides 1.738e‐14 ‐??
rs35207557  chr1:11.9  NPPB 
(NTPROBNP) 
0 NPPB 2.6E‐25 ‐0.26 T/TA 0.6 0.98  Natriuretic peptides B 2.57e‐25 ‐??
rs184243355  chr5:153.2  CCL3  trans 2.2E‐08 ‐0.41 T/C 0.94 0.47  C‐C motif chemokine 3 2.239e‐08 ‐??
rs61598054  chr6:108.8  NGF (BETANGF)  trans FOXO3 3.8E‐08 ‐0.31 C/T 0.87 0.42  Beta‐nerve growth factor 3.802e‐08 ‐??
rs6557662  chr8:23.2  NPPB 
(NTPROBNP) 
trans 1.5E‐08 0.23 A/G 0.73 0.44  Natriuretic peptides B 1.479e‐08 +??
rs139879640  chr15:81.6  IL16  0 IL16 3E‐62 0.86 TCTCA/ 0.94 0.96  Pro‐interleukin‐16 [Cleaved into: 
Interleukin‐16 
2.951e‐62 +??
rs200433550  chr19:49.2  F3 (TF)  trans 5.6E‐10 0.16 TA/T 0.58 0.91  Tissue factor 5.623e‐10 +??
rs2050011  chrX:128.9  XPNPEP2 
(MAMP) 
‐1 XPNPEP2 2.4E‐68 ‐0.36 T/G 0.33 1.05  Xaa‐Pro aminopeptidase 2 2.399e‐68 ‐??
Overview of all associations between plasma protein and SNPs significant at genome‐wide level. Trait – the plasma protein target; Dist (kb) – if 
cis, the distance between SNP and protein encoding gene; Likely mediator gene – most likely cis‐mediator gene, protein‐encoding gene in cis‐
cases, based on table 2 in trans cases; Discovery P – the pQTL association P‐value from the Olink‐Improve discovery cohort  (n=3,394); Discovery 
Beta – the Olink‐Improve effect size; A1/A2 – encoded allele and alternative allele; A1 freq – frequency of encoded allele; INFO – imputation 
quality score (MACH 1.0). Protein name; Replication P ‐ the pQTL association P‐value from the replication cohorts (n=976, n=933,n=730); 
Combined P – the meta‐analysis P‐value of both discovery and replication; Directions ‐ for replication meta‐analysis are indicated as IMPROVE 
(discovery), NSPHS (replication), ULSAM‐PIVUS (merged replication). †while 530.7 kb is formally outside of the pre‐defined cis‐limit of 500 kb, 
the AGRP association was classified as cis‐acting; all other pQTL associations were either acting across chromosomes or at distances more than 
100 MB. SE: standard error.    
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Table	S2	
Other trait  Other SNP  r2 (EUR 
1000G) 
Other P‐
value 
Pubmed ID  Olink SNP  Olink Trait 
Protein 
Olink P‐
value 
DBP  rs6668659  0.67  5.1E‐10  24560520  rs549596  BNP  1.75E‐14 
Mean Arterial Pressure  rs6668659  0.67  1.2E‐09  24560520  rs549596  BNP  1.75E‐14 
SBP  rs6668659  0.67  4.5E‐09  24560520  rs549596  BNP  1.75E‐14 
HDL cholesterol  rs12748152  0.92  1.0E‐15  24097068  rs35538083  XPNPEP2  3.11E‐08 
LDL cholesterol  rs12748152  0.92  3.0E‐12  24097068  rs35538083  XPNPEP2  3.11E‐08 
Triglycerides  rs12748152  0.92  1.0E‐09  24097068  rs35538083  XPNPEP2  3.11E‐08 
Interleukin‐6_receptor|CSF|(gene=IL6R)  rs4129267  1.00  2.7E‐62  25340798  rs4129267  IL6R  2.14E‐265 
IL6RA|plasma|(gene=IL6R)  rs4129267  1.00  4.4E‐58  25147954  rs4129267  IL6R  2.14E‐265 
Protein quantitative trait loci (sIL‐6R)  rs4129267  1.00  2.0E‐57  18464913  rs4129267  IL6R  2.14E‐265 
C‐reactive protein  rs4129267  1.00  2.0E‐48  21300955  rs4129267  IL6R  2.14E‐265 
Fibrinogen|plasma  rs61812598  1.00  2.7E‐36  26561523  rs4129267  IL6R  2.14E‐265 
Fibrinogen (EA)  rs4129267  1.00  6.0E‐27  23969696  rs4129267  IL6R  2.14E‐265 
Ankylosing spondylitis  rs4129267  1.00  3.4E‐13  23749187  rs4129267  IL6R  2.14E‐265 
Asthma  rs4129267  1.00  2.0E‐08  21907864  rs4129267  IL6R  2.14E‐265 
Fibrinogen  rs2228145  0.99  2.0E‐11  20031577  rs4129267  IL6R  2.14E‐265 
Rheumatoid arthritis  rs2228145  0.99  4.0E‐09  24390342  rs4129267  IL6R  2.14E‐265 
YKL‐40 levels  rs4950928  0.90  1.0E‐13  18403759  rs2153101  CHI3L1  7.50E‐108 
Triglycerides  rs1260326  1.00  2.0E‐239  24097068  rs1260326  FST  2.02E‐09 
Blood metabolite ratios (glucose/mannose)  rs1260326  1.00  3.0E‐148  24816252  rs1260326  FST  2.02E‐09 
Blood metabolite levels (mannose)  rs1260326  1.00  1.0E‐77  24816252  rs1260326  FST  2.02E‐09 
Urate levels  rs1260326  1.00  1.0E‐44  23263486  rs1260326  FST  2.02E‐09 
Tryglycerides transethnic  rs1260326  1.00  1.6E‐42  23555291  rs1260326  FST  2.02E‐09 
Cholesterol, total  rs1260326  1.00  3.0E‐42  24097068  rs1260326  FST  2.02E‐09 
Fasting glucose‐ BMI‐adjusted   rs1260326  1.00  1.0E‐40  22885924  rs1260326  FST  2.02E‐09 
Fasting glucose  rs1260326  1.00  1.0E‐40  22885924  rs1260326  FST  2.02E‐09 
C‐reactive protein  rs1260326  1.00  5.0E‐40  21300955  rs1260326  FST  2.02E‐09 
Lipid metabolism phenotypes (TG.assay, whole)  rs1260326  1.00  1.0E‐37  19936222  rs1260326  FST  2.02E‐09 
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Lipid metabolism phenotypes (TG.by.NMR, 
whole) 
rs1260326  1.00  3.0E‐35  19936222  rs1260326  FST  2.02E‐09 
Lipid metabolism phenotypes (TG.assay, fasting)  rs1260326  1.00  4.0E‐32  19936222  rs1260326  FST  2.02E‐09 
Lipid metabolism phenotypes (TG.by.NMR, 
fasting) 
rs1260326  1.00  3.0E‐29  19936222  rs1260326  FST  2.02E‐09 
Lipid metabolism phenotypes (VLDL.large, 
whole) 
rs1260326  1.00  3.0E‐28  19936222  rs1260326  FST  2.02E‐09 
Lipid metabolism phenotypes (VLDL.large, 
fasting) 
rs1260326  1.00  4.0E‐24  19936222  rs1260326  FST  2.02E‐09 
Fasting Insulin‐ BMI adjusted  rs1260326  1.00  2.7E‐22  22885924  rs1260326  FST  2.02E‐09 
Serum albumin level  rs1260326  1.00  4.0E‐19  23022100  rs1260326  FST  2.02E‐09 
Metabolite levels (Ala, Gln)  rs1260326  1.00  3.0E‐18  22286219  rs1260326  FST  2.02E‐09 
2 hr glucose ‐FG and BMI adjusted  rs1260326  1.00  9.0E‐15  22885924  rs1260326  FST  2.02E‐09 
Chronic kidney disease (eGFRcrea)  rs1260326  1.00  3.0E‐14  20383146  rs1260326  FST  2.02E‐09 
Serum albumin level (EA)  rs1260326  1.00  3.0E‐14  23022100  rs1260326  FST  2.02E‐09 
Fasting Insulin  rs1260326  1.00  3.8E‐14  22885924  rs1260326  FST  2.02E‐09 
Blood metabolite levels (alanine)  rs1260326  1.00  6.0E‐14  24816252  rs1260326  FST  2.02E‐09 
Hypertriglyceridemia  rs1260326  1.00  2.0E‐13  23505323  rs1260326  FST  2.02E‐09 
Liver enzyme levels (gamma‐glutamyl 
transferase) 
rs1260326  1.00  4.0E‐13  22001757  rs1260326  FST  2.02E‐09 
Glycemic traits (pregnancy) (FPG)  rs1260326  1.00  6.0E‐13  23903356  rs1260326  FST  2.02E‐09 
Metabolite levels  rs1260326  1.00  1.0E‐12  22916037  rs1260326  FST  2.02E‐09 
Alanine  rs1260326  1.00  7.6E‐12  23823483  rs1260326  FST  2.02E‐09 
PC aa C40:5  rs1260326  1.00  1.3E‐11  26068415  rs1260326  FST  2.02E‐09 
Lactate  rs1260326  1.00  3.3E‐11  23823483  rs1260326  FST  2.02E‐09 
Glycemic traits (pregnancy) (FCP)  rs1260326  1.00  6.0E‐11  23903356  rs1260326  FST  2.02E‐09 
Two‐hour glucose challenge  rs1260326  1.00  3.0E‐10  20081857  rs1260326  FST  2.02E‐09 
Metabolic traits (TG)  rs1260326  1.00  4.0E‐10  19060910  rs1260326  FST  2.02E‐09 
Platelet counts  rs1260326  1.00  9.0E‐10  22139419  rs1260326  FST  2.02E‐09 
α‐hydroxybutyrate  rs1260326  1.00  1.3E‐09  23823483  rs1260326  FST  2.02E‐09 
Non‐albumin protein levels  (ALB)  rs1260326  1.00  3.0E‐09  22558069  rs1260326  FST  2.02E‐09 
TAG 50:4  rs1260326  1.00  3.4E‐09  23823483  rs1260326  FST  2.02E‐09 
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Hematological and biochemical traits (ALB)  rs1260326  1.00  4.0E‐09  20139978  rs1260326  FST  2.02E‐09 
Cardiovascular disease risk factors (TRIG)  rs1260326  1.00  2.0E‐08  21943158  rs1260326  FST  2.02E‐09 
Serum albumin level (Japanese)  rs1260326  1.00  2.0E‐08  23022100  rs1260326  FST  2.02E‐09 
TAG 48:2  rs1260326  1.00  2.5E‐08  23823483  rs1260326  FST  2.02E‐09 
TAG 50:3  rs1260326  1.00  2.6E‐08  23823483  rs1260326  FST  2.02E‐09 
PC 34:3  rs1260326  1.00  2.9E‐08  23823483  rs1260326  FST  2.02E‐09 
PC 32:2  rs1260326  1.00  3.9E‐08  23823483  rs1260326  FST  2.02E‐09 
Waist circumference and related phenotypes 
(triglycerides) 
rs1260326  1.00  4.0E‐08  18454146  rs1260326  FST  2.02E‐09 
TAG 48:3  rs1260326  1.00  4.9E‐08  23823483  rs1260326  FST  2.02E‐09 
Urate levels (Urate)  rs780093  0.91  4.0E‐17  20884846  rs1260326  FST  2.02E‐09 
Sex hormone‐binding globulin levels (Men + 
Women) 
rs780093  0.91  2.0E‐16  22829776  rs1260326  FST  2.02E‐09 
Waist Circumference ‐ Triglycerides (WC‐TG)  rs780093  0.91  2.0E‐12  21386085  rs1260326  FST  2.02E‐09 
Crohn's disease  rs780093  0.91  5.0E‐11  21102463  rs1260326  FST  2.02E‐09 
Sex hormone‐binding globulin levels (Women)  rs780093  0.91  9.0E‐11  22829776  rs1260326  FST  2.02E‐09 
Triglycerides‐Blood Pressure (TG‐BP)  rs780093  0.91  3.0E‐10  21386085  rs1260326  FST  2.02E‐09 
Palmitoleic acid (16:1n‐7) plasma levels  rs780093  0.91  1.0E‐09  23362303  rs1260326  FST  2.02E‐09 
Metabolic traits (glucose/mannose + 54 other 
traits) 
rs780094  0.90  6.0E‐53  21886157  rs1260326  FST  2.02E‐09 
Fasting glucose‐related traits (FPG)  rs780094  0.90  6.0E‐38  20081858  rs1260326  FST  2.02E‐09 
Fasting glucose‐related traits (HOMA‐IR)  rs780094  0.90  3.0E‐24  20081858  rs1260326  FST  2.02E‐09 
Fasting insulin‐related traits (HOMA‐IR)  rs780094  0.90  3.0E‐24  20081858  rs1260326  FST  2.02E‐09 
Fasting glucose‐related traits (interaction with 
BMI) 
rs780094  0.90  4.0E‐24  22581228  rs1260326  FST  2.02E‐09 
Fasting insulin‐related traits (FI)  rs780094  0.90  4.0E‐20  20081858  rs1260326  FST  2.02E‐09 
Fasting glucose‐related traits (FI)  rs780094  0.90  4.0E‐20  20081858  rs1260326  FST  2.02E‐09 
Metabolic syndrome (TG)  rs780094  0.90  6.0E‐20  22399527  rs1260326  FST  2.02E‐09 
height  rs780094  0.90  7.5E‐12  25282103  rs1260326  FST  2.02E‐09 
Calcium levels  rs780094  0.90  1.0E‐10  24068962  rs1260326  FST  2.02E‐09 
Fasting insulin‐related traits (interaction with 
BMI) 
rs780094  0.90  3.0E‐10  22581228  rs1260326  FST  2.02E‐09 
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Uric acid levels  rs780094  0.90  1.0E‐09  19503597  rs1260326  FST  2.02E‐09 
Fasting plasma glucose (East Asian)  rs780094  0.90  3.6E‐09  25187374  rs1260326  FST  2.02E‐09 
Triglycerides (Hispanic)  rs780094  0.90  7.0E‐09  23726366  rs1260326  FST  2.02E‐09 
Phospholipid levels (plasma) (DPA)  rs780094  0.90  9.0E‐09  21829377  rs1260326  FST  2.02E‐09 
Triglycerides (AA)  rs4665972  0.87  1.0E‐08  23726366  rs1260326  FST  2.02E‐09 
Inflammatory biomarkers (IL18)  rs7577696  0.77  3.0E‐19  24182552  rs693918  IL18  2.38E‐11 
Eosinophil counts (EA)  rs1420101  1.00  5.0E‐14  19198610  rs1420101  IL1RL1  2.03E‐132 
Serum protein levels (sST2)  rs950880  0.97  7.0E‐94  23999434  rs1420101  IL1RL1  2.03E‐132 
Pulmonary function (interaction) (FEV1/FVC, 
Pack‐years) 
rs2070600  1.00  1.0E‐21  23284291  rs2070600  AGER  3.01E‐10 
Pulmonary function (FEV1/FVC)  rs2070600  1.00  3.0E‐14  20010835  rs2070600  AGER  3.01E‐10 
Crohn's disease  rs10947261  0.97  3.0E‐12  23850713  rs10947260  IL6  1.83E‐10 
Knee osteoarthritis  rs10947262  0.97  5.0E‐09  20305777  rs10947260  IL6  1.83E‐10 
Vascular endothelial growth factor levels  rs6993770  1.00  5.0E‐23  21757650  rs6993770  DKK1  1.61E‐09 
Platelet counts  rs6993770  1.00  4.0E‐17  22139419  rs6993770  DKK1  1.61E‐09 
Vascular endothelial growth factor levels  rs6993770  0.80  5.0E‐23  21757650  rs16873402  PDGFB  2.42E‐08 
Platelet counts  rs6993770  0.80  4.0E‐17  22139419  rs16873402  PDGFB  2.42E‐08 
Triglycerides  rs2954029  0.74  1.0E‐107  24097068  rs28601761  CHI3L1  5.06E‐09 
Cholesterol, total  rs2954029  0.74  2.0E‐65  24097068  rs28601761  CHI3L1  5.06E‐09 
LDL cholesterol  rs2954029  0.74  2.0E‐50  24097068  rs28601761  CHI3L1  5.06E‐09 
HDL cholesterol  rs2954029  0.74  3.0E‐29  24097068  rs28601761  CHI3L1  5.06E‐09 
CAD  rs2954029  0.74  4.8E‐09  23202125  rs28601761  CHI3L1  5.06E‐09 
Lipid metabolism phenotypes (APOB.assay, 
whole) 
rs6982636  0.71  7.0E‐12  19936222  rs28601761  CHI3L1  5.06E‐09 
Lipid metabolism phenotypes (TG.assay, whole)  rs6982636  0.71  1.0E‐09  19936222  rs28601761  CHI3L1  5.06E‐09 
Liver enzyme levels (alkaline phosphatase)  rs2954021  0.64  2.0E‐13  22001757  rs28601761  CHI3L1  5.06E‐09 
Liver enzyme levels (alanine transaminase)  rs2954021  0.64  5.0E‐09  22001757  rs28601761  CHI3L1  5.06E‐09 
Elevated serum carcinoembryonic antigen levels  rs8176741  1.00  2.0E‐24  24941225  rs8176741  TEK  8.63E‐50 
Tumor biomarkers (CEA)  rs8176749  0.98  7.0E‐105  23300138  rs8176741  TEK  8.63E‐50 
sTie‐2|plasma|(gene=TEK)  rs8176693  0.98  1.8E‐33  25552591  rs8176741  TEK  8.63E‐50 
vWF  rs8176693  0.98  1.6E‐17  23381943  rs8176741  TEK  8.63E‐50 
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End‐stage coagulation (vWF)  rs8176743  0.98  2.0E‐17  23381943  rs8176741  TEK  8.63E‐50 
FVIII Ag  rs8176693  0.98  1.2E‐14  23381943  rs8176741  TEK  8.63E‐50 
Urinary metabolites (H‐NMR features) (5.2625, 
Unknown) 
rs8176749  0.98  4.0E‐12  24586186  rs8176741  TEK  8.63E‐50 
Ang‐2|plasma|(gene=MCPH1)  rs8176746  0.98  2.1E‐08  25552591  rs8176741  TEK  8.63E‐50 
Mean corpuscular hemoglobin concentration  rs8176746  0.98  4.0E‐08  20139978  rs8176741  TEK  8.63E‐50 
Malaria  rs8176722  0.70  9.0E‐10  23717212  rs8176741  TEK  8.63E‐50 
Tumor biomarkers (CEA)  rs8176749  1.00  7.0E‐105  23300138  rs8176693  THBD  1.12E‐10 
sTie‐2|plasma|(gene=TEK)  rs8176693  1.00  1.8E‐33  25552591  rs8176693  THBD  1.12E‐10 
vWF  rs8176693  1.00  1.6E‐17  23381943  rs8176693  THBD  1.12E‐10 
End‐stage coagulation (vWF)  rs8176743  1.00  2.0E‐17  23381943  rs8176693  THBD  1.12E‐10 
FVIII Ag  rs8176693  1.00  1.2E‐14  23381943  rs8176693  THBD  1.12E‐10 
Urinary metabolites (H‐NMR features) (5.2625, 
Unknown) 
rs8176749  1.00  4.0E‐12  24586186  rs8176693  THBD  1.12E‐10 
Ang‐2|plasma|(gene=MCPH1)  rs8176746  1.00  2.1E‐08  25552591  rs8176693  THBD  1.12E‐10 
Mean corpuscular hemoglobin concentration  rs8176746  1.00  4.0E‐08  20139978  rs8176693  THBD  1.12E‐10 
Elevated serum carcinoembryonic antigen levels  rs8176741  0.98  2.0E‐24  24941225  rs8176693  THBD  1.12E‐10 
Malaria  rs8176722  0.71  9.0E‐10  23717212  rs8176693  THBD  1.12E‐10 
Liver enzyme levels (alkaline phosphatase)  rs579459  1.00  3.0E‐123  22001757  rs495828  F3  4.54E‐10 
E‐selectin|plasma|(gene=SELE)  rs651007  1.00  1.9E‐103  23300549  rs495828  F3  4.54E‐10 
E‐selectin levels  rs651007  1.00  2.0E‐82  20147318  rs495828  F3  4.54E‐10 
Hematological and biochemical traits (ALP)  rs495828  1.00  4.0E‐59  20139978  rs495828  F3  4.54E‐10 
Serum alkaline phosphatase levels  rs651007  1.00  1.0E‐56  24094242  rs495828  F3  4.54E‐10 
Soluble levels of adhesion molecules (P‐
Selectin) 
rs579459  1.00  2.0E‐41  20167578  rs495828  F3  4.54E‐10 
Blood metabolite ratios 
(ADSGEGDFXAEGGGVR/ADpSGEGDFXAEGGGVR
) 
rs649129  1.00  9.0E‐37  24816252  rs495828  F3  4.54E‐10 
Blood metabolite ratios 
(DSGEGDFXAEGGGVR/ADpSGEGDFXAEGGGVR) 
rs495828  1.00  6.0E‐34  24816252  rs495828  F3  4.54E‐10 
Urinary metabolites (H‐NMR features) (5.1825, 
Unknown) 
rs579459  1.00  2.0E‐32  24586186  rs495828  F3  4.54E‐10 
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Soluble E‐selectin levels  rs579459  1.00  1.0E‐29  19729612  rs495828  F3  4.54E‐10 
Blood metabolite ratios 
(ADpSGEGDFXAEGGGVR/X‐14304‐‐
leucylalanine) 
rs579459  1.00  1.0E‐28  24816252  rs495828  F3  4.54E‐10 
Urinary metabolites (H‐NMR features) (2.0525, 
Unknown) 
rs579459  1.00  1.0E‐28  24586186  rs495828  F3  4.54E‐10 
End‐stage coagulation (FVIII)  rs651007  1.00  2.0E‐25  23381943  rs495828  F3  4.54E‐10 
Blood metabolite levels 
(ADpSGEGDFXAEGGGVR) 
rs651007  1.00  6.0E‐20  24816252  rs495828  F3  4.54E‐10 
Red blood cell traits (EA, RBCC)  rs579459  1.00  9.0E‐18  23222517  rs495828  F3  4.54E‐10 
Venous thromboembolism  rs495828  1.00  3.0E‐16  22672568  rs495828  F3  4.54E‐10 
Soluble levels of adhesion molecules (ICAM)  rs649129  1.00  1.0E‐15  20167578  rs495828  F3  4.54E‐10 
Coronary heart disease  rs579459  1.00  4.0E‐14  21378990  rs495828  F3  4.54E‐10 
vWF  rs495828  1.00  9.4E‐13  23381943  rs495828  F3  4.54E‐10 
Red blood cell count  rs495828  1.00  3.0E‐12  20139978  rs495828  F3  4.54E‐10 
Hematological and biochemical traits (Hb)  rs495828  1.00  1.0E‐11  20139978  rs495828  F3  4.54E‐10 
Hematological and biochemical traits (Ht)  rs495828  1.00  6.0E‐10  20139978  rs495828  F3  4.54E‐10 
Coronary artery disease or ischemic stroke  rs579459  1.00  2.0E‐09  24262325  rs495828  F3  4.54E‐10 
Metabolite levels (LDL)  rs651007  1.00  6.0E‐09  21909109  rs495828  F3  4.54E‐10 
Ferritin (log)|serum|(gene=FTL|FTH1)  rs651007  1.00  1.3E‐08  25352340  rs495828  F3  4.54E‐10 
CAD  rs579459  1.00  2.7E‐08  23202125  rs495828  F3  4.54E‐10 
Coronary artery disease or large artery stroke  rs579459  1.00  3.0E‐08  24262325  rs495828  F3  4.54E‐10 
Angiotensin‐converting enzyme activity  rs495828  1.00  3.0E‐08  20066004  rs495828  F3  4.54E‐10 
FVIII Ag  rs495828  1.00  3.7E‐08  23381943  rs495828  F3  4.54E‐10 
LDL cholesterol  rs635634  0.83  2.0E‐41  24097068  rs495828  F3  4.54E‐10 
Cholesterol, total  rs635634  0.83  3.0E‐35  24097068  rs495828  F3  4.54E‐10 
invasive epithelial ovarian cancer  rs635634  0.83  4.4E‐09  25581431  rs495828  F3  4.54E‐10 
Soluble ICAM‐1  rs507666  0.83  3.0E‐91  21533024  rs495828  F3  4.54E‐10 
Lipid traits (LDL)  rs507666  0.83  2.0E‐11  24386095  rs495828  F3  4.54E‐10 
Lipid traits (TC)  rs507666  0.83  4.0E‐11  24386095  rs495828  F3  4.54E‐10 
LDL‐C transethnic  rs2519093  0.82  2.2E‐13  23555291  rs495828  F3  4.54E‐10 
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LDL cholesterol  rs635634  1.00  2.0E‐41  24097068  rs635634  PECAM1  1.89E‐45 
Cholesterol, total  rs635634  1.00  3.0E‐35  24097068  rs635634  PECAM1  1.89E‐45 
E‐selectin|plasma|(gene=SELE)  rs635634  1.00  5.0E‐16  25147954  rs635634  PECAM1  1.89E‐45 
invasive epithelial ovarian cancer  rs635634  1.00  4.4E‐09  25581431  rs635634  PECAM1  1.89E‐45 
Soluble ICAM‐1  rs507666  0.99  3.0E‐91  21533024  rs635634  PECAM1  1.89E‐45 
Lipid traits (LDL)  rs507666  0.99  2.0E‐11  24386095  rs635634  PECAM1  1.89E‐45 
Lipid traits (TC)  rs507666  0.99  4.0E‐11  24386095  rs635634  PECAM1  1.89E‐45 
Venous thromboembolism  rs2519093  0.98  8.0E‐16  22672568  rs635634  PECAM1  1.89E‐45 
LDL‐C transethnic  rs2519093  0.98  2.2E‐13  23555291  rs635634  PECAM1  1.89E‐45 
CAD  rs2519093  0.98  1.2E‐11  26343387  rs635634  PECAM1  1.89E‐45 
Liver enzyme levels (alkaline phosphatase)  rs579459  0.83  3.0E‐123  22001757  rs635634  PECAM1  1.89E‐45 
E‐selectin levels  rs651007  0.83  2.0E‐82  20147318  rs635634  PECAM1  1.89E‐45 
Hematological and biochemical traits (ALP)  rs495828  0.83  4.0E‐59  20139978  rs635634  PECAM1  1.89E‐45 
Serum alkaline phosphatase levels  rs651007  0.83  1.0E‐56  24094242  rs635634  PECAM1  1.89E‐45 
Soluble levels of adhesion molecules (P‐
Selectin) 
rs579459  0.83  2.0E‐41  20167578  rs635634  PECAM1  1.89E‐45 
Blood metabolite ratios 
(ADSGEGDFXAEGGGVR/ADpSGEGDFXAEGGGVR
) 
rs649129  0.83  9.0E‐37  24816252  rs635634  PECAM1  1.89E‐45 
Blood metabolite ratios 
(DSGEGDFXAEGGGVR/ADpSGEGDFXAEGGGVR) 
rs495828  0.83  6.0E‐34  24816252  rs635634  PECAM1  1.89E‐45 
Urinary metabolites (H‐NMR features) (5.1825, 
Unknown) 
rs579459  0.83  2.0E‐32  24586186  rs635634  PECAM1  1.89E‐45 
Soluble E‐selectin levels  rs579459  0.83  1.0E‐29  19729612  rs635634  PECAM1  1.89E‐45 
Blood metabolite ratios 
(ADpSGEGDFXAEGGGVR/X‐14304‐‐
leucylalanine) 
rs579459  0.83  1.0E‐28  24816252  rs635634  PECAM1  1.89E‐45 
Urinary metabolites (H‐NMR features) (2.0525, 
Unknown) 
rs579459  0.83  1.0E‐28  24586186  rs635634  PECAM1  1.89E‐45 
End‐stage coagulation (FVIII)  rs651007  0.83  2.0E‐25  23381943  rs635634  PECAM1  1.89E‐45 
Blood metabolite levels 
(ADpSGEGDFXAEGGGVR) 
rs651007  0.83  6.0E‐20  24816252  rs635634  PECAM1  1.89E‐45 
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Red blood cell traits (EA, RBCC)  rs579459  0.83  9.0E‐18  23222517  rs635634  PECAM1  1.89E‐45 
Soluble levels of adhesion molecules (ICAM)  rs649129  0.83  1.0E‐15  20167578  rs635634  PECAM1  1.89E‐45 
Coronary heart disease  rs579459  0.83  4.0E‐14  21378990  rs635634  PECAM1  1.89E‐45 
vWF  rs579459  0.83  9.9E‐13  23381943  rs635634  PECAM1  1.89E‐45 
Red blood cell count  rs495828  0.83  3.0E‐12  20139978  rs635634  PECAM1  1.89E‐45 
Hematological and biochemical traits (Hb)  rs495828  0.83  1.0E‐11  20139978  rs635634  PECAM1  1.89E‐45 
Hematological and biochemical traits (Ht)  rs495828  0.83  6.0E‐10  20139978  rs635634  PECAM1  1.89E‐45 
Coronary artery disease or ischemic stroke  rs579459  0.83  2.0E‐09  24262325  rs635634  PECAM1  1.89E‐45 
Metabolite levels (LDL)  rs651007  0.83  6.0E‐09  21909109  rs635634  PECAM1  1.89E‐45 
Ferritin (log)|serum|(gene=FTL|FTH1)  rs651007  0.83  1.3E‐08  25352340  rs635634  PECAM1  1.89E‐45 
FVIII Ag  rs579459  0.83  2.3E‐08  23381943  rs635634  PECAM1  1.89E‐45 
Coronary artery disease or large artery stroke  rs579459  0.83  3.0E‐08  24262325  rs635634  PECAM1  1.89E‐45 
Angiotensin‐converting enzyme activity  rs495828  0.83  3.0E‐08  20066004  rs635634  PECAM1  1.89E‐45 
LDL cholesterol  rs635634  1.00  2.0E‐41  24097068  rs635634  SELE  9.64E‐220 
Cholesterol, total  rs635634  1.00  3.0E‐35  24097068  rs635634  SELE  9.64E‐220 
E‐selectin|plasma|(gene=SELE)  rs635634  1.00  5.0E‐16  25147954  rs635634  SELE  9.64E‐220 
invasive epithelial ovarian cancer  rs635634  1.00  4.4E‐09  25581431  rs635634  SELE  9.64E‐220 
Soluble ICAM‐1  rs507666  0.99  3.0E‐91  21533024  rs635634  SELE  9.64E‐220 
Lipid traits (LDL)  rs507666  0.99  2.0E‐11  24386095  rs635634  SELE  9.64E‐220 
Lipid traits (TC)  rs507666  0.99  4.0E‐11  24386095  rs635634  SELE  9.64E‐220 
Venous thromboembolism  rs2519093  0.98  8.0E‐16  22672568  rs635634  SELE  9.64E‐220 
LDL‐C transethnic  rs2519093  0.98  2.2E‐13  23555291  rs635634  SELE  9.64E‐220 
CAD  rs2519093  0.98  1.2E‐11  26343387  rs635634  SELE  9.64E‐220 
Liver enzyme levels (alkaline phosphatase)  rs579459  0.83  3.0E‐123  22001757  rs635634  SELE  9.64E‐220 
E‐selectin levels  rs651007  0.83  2.0E‐82  20147318  rs635634  SELE  9.64E‐220 
Hematological and biochemical traits (ALP)  rs495828  0.83  4.0E‐59  20139978  rs635634  SELE  9.64E‐220 
Serum alkaline phosphatase levels  rs651007  0.83  1.0E‐56  24094242  rs635634  SELE  9.64E‐220 
Soluble levels of adhesion molecules (P‐
Selectin) 
rs579459  0.83  2.0E‐41  20167578  rs635634  SELE  9.64E‐220 
Blood metabolite ratios 
(ADSGEGDFXAEGGGVR/ADpSGEGDFXAEGGGVR
rs649129  0.83  9.0E‐37  24816252  rs635634  SELE  9.64E‐220 
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) 
Blood metabolite ratios 
(DSGEGDFXAEGGGVR/ADpSGEGDFXAEGGGVR) 
rs495828  0.83  6.0E‐34  24816252  rs635634  SELE  9.64E‐220 
Urinary metabolites (H‐NMR features) (5.1825, 
Unknown) 
rs579459  0.83  2.0E‐32  24586186  rs635634  SELE  9.64E‐220 
Soluble E‐selectin levels  rs579459  0.83  1.0E‐29  19729612  rs635634  SELE  9.64E‐220 
Blood metabolite ratios 
(ADpSGEGDFXAEGGGVR/X‐14304‐‐
leucylalanine) 
rs579459  0.83  1.0E‐28  24816252  rs635634  SELE  9.64E‐220 
Urinary metabolites (H‐NMR features) (2.0525, 
Unknown) 
rs579459  0.83  1.0E‐28  24586186  rs635634  SELE  9.64E‐220 
End‐stage coagulation (FVIII)  rs651007  0.83  2.0E‐25  23381943  rs635634  SELE  9.64E‐220 
Blood metabolite levels 
(ADpSGEGDFXAEGGGVR) 
rs651007  0.83  6.0E‐20  24816252  rs635634  SELE  9.64E‐220 
Red blood cell traits (EA, RBCC)  rs579459  0.83  9.0E‐18  23222517  rs635634  SELE  9.64E‐220 
Soluble levels of adhesion molecules (ICAM)  rs649129  0.83  1.0E‐15  20167578  rs635634  SELE  9.64E‐220 
Coronary heart disease  rs579459  0.83  4.0E‐14  21378990  rs635634  SELE  9.64E‐220 
vWF  rs579459  0.83  9.9E‐13  23381943  rs635634  SELE  9.64E‐220 
Red blood cell count  rs495828  0.83  3.0E‐12  20139978  rs635634  SELE  9.64E‐220 
Hematological and biochemical traits (Hb)  rs495828  0.83  1.0E‐11  20139978  rs635634  SELE  9.64E‐220 
Hematological and biochemical traits (Ht)  rs495828  0.83  6.0E‐10  20139978  rs635634  SELE  9.64E‐220 
Coronary artery disease or ischemic stroke  rs579459  0.83  2.0E‐09  24262325  rs635634  SELE  9.64E‐220 
Metabolite levels (LDL)  rs651007  0.83  6.0E‐09  21909109  rs635634  SELE  9.64E‐220 
Ferritin (log)|serum|(gene=FTL|FTH1)  rs651007  0.83  1.3E‐08  25352340  rs635634  SELE  9.64E‐220 
FVIII Ag  rs579459  0.83  2.3E‐08  23381943  rs635634  SELE  9.64E‐220 
Coronary artery disease or large artery stroke  rs579459  0.83  3.0E‐08  24262325  rs635634  SELE  9.64E‐220 
Angiotensin‐converting enzyme activity  rs495828  0.83  3.0E‐08  20066004  rs635634  SELE  9.64E‐220 
Height  rs11599750  1.00  2.0E‐13  20881960  rs11599750  IL27  1.40E‐10 
height  rs11599750  1.00  4.7E‐13  25282103  rs11599750  IL27  1.40E‐10 
Bone mineral density (FNBMD)  rs7084921  0.88  9.0E‐10  22504420  rs11599750  IL27  1.40E‐10 
Age‐related hearing impairment (interaction)  rs4462272  0.62  8.0E‐09  24939585  rs11599750  IL27  1.40E‐10 
Circulating vasoactive peptide levels  (ADM)  rs2957692  0.63  1.0E‐12  23381795  rs1580006  ADM  2.04E‐15 
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Matrix_Metalloproteinase‐
3|CSF|(gene=MMP3) 
rs471994  1.00  2.3E‐21  25340798  rs471994  MMP1  2.34E‐35 
Matrix metalloproteinase levels  rs495366  0.72  6.0E‐34  20031604  rs471994  MMP1  2.34E‐35 
Matrix_Metalloproteinase‐
3|CSF|(gene=MMP3) 
rs7946057  1.00  2.4E‐42  25340798  rs7946057  MMP3  1.22E‐108 
Matrix metalloproteinase levels  rs11225434  0.94  9.0E‐29  20031604  rs7946057  MMP3  1.22E‐108 
Chronic obstructive pulmonary disease (severe)  rs626750  0.64  3.0E‐09  24621683  rs17368659  MMP12  5.52E‐97 
Interleukin‐18 levels  rs1834481  0.79  1.0E‐08  20150558  rs75649625  IL18  1.46E‐21 
C‐reactive protein  rs1169310  1.00  2.0E‐08  18439552  rs1169306  LGALS3  6.47E‐09 
N‐glycan levels (DG11)  rs735396  1.00  4.0E‐08  21203500  rs1169306  LGALS3  6.47E‐09 
C‐reactive protein (HA women)  rs2259816  0.99  3.0E‐10  22939635  rs1169306  LGALS3  6.47E‐09 
Liver enzyme levels (GGT)  rs1169313  0.98  2.0E‐10  18940312  rs1169306  LGALS3  6.47E‐09 
Gamma glutamyl transpeptidase  rs2393791  0.73  7.0E‐30  21909109  rs1169306  LGALS3  6.47E‐09 
C‐reactive protein levels  rs2393791  0.73  3.0E‐10  24763700  rs1169306  LGALS3  6.47E‐09 
C‐reactive protein and white blood cell count 
(CRP) 
rs2393791  0.73  3.0E‐09  22788528  rs1169306  LGALS3  6.47E‐09 
Liver enzyme levels (gamma‐glutamyl 
transferase) 
rs7310409  0.73  7.0E‐45  22001757  rs1169306  LGALS3  6.47E‐09 
Urate levels  rs7188445  0.98  2.0E‐09  23263486  rs11150189  XPNPEP2  7.00E‐14 
Thyroid hormone levels (TSH)  rs3813582  0.92  8.0E‐18  23408906  rs11150189  XPNPEP2  7.00E‐14 
Thyroid hormone levels (TSH ‐ Males)  rs3813582  0.92  6.0E‐17  23408906  rs11150189  XPNPEP2  7.00E‐14 
Thyroid volume (thyroid volume)  rs17767419  0.92  9.0E‐15  21565293  rs11150189  XPNPEP2  7.00E‐14 
Thyroid function  rs3813582  0.92  6.0E‐10  22494929  rs11150189  XPNPEP2  7.00E‐14 
Vitamin B12 levels  rs492602  1.00  5.0E‐17  18776911  rs492602  MMP10  7.69E‐09 
Cholesterol, total  rs492602  1.00  1.0E‐16  24097068  rs492602  MMP10  7.69E‐09 
Blood metabolite ratios 
(ADSGEGDFXAEGGGVR/ADpSGEGDFXAEGGGVR
) 
rs601338  0.99  2.0E‐20  24816252  rs492602  MMP10  7.69E‐09 
Crohn's disease  rs516246  0.99  1.0E‐15  23128233  rs492602  MMP10  7.69E‐09 
Blood metabolite levels 
(ADpSGEGDFXAEGGGVR) 
rs601338  0.99  3.0E‐11  24816252  rs492602  MMP10  7.69E‐09 
Liver enzyme levels (gamma‐glutamyl  rs516246  0.99  8.0E‐10  22001757  rs492602  MMP10  7.69E‐09 
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transferase) 
Folate pathway vitamin levels (vitamin B12)  rs602662  0.89  3.0E‐20  19303062  rs492602  MMP10  7.69E‐09 
Folate pathway vitamin levels (Plasma Vitamin 
B12) 
rs602662  0.89  2.0E‐15  19744961  rs492602  MMP10  7.69E‐09 
Metabolic traits (SM‐11 + 2 other traits)  rs503279  0.89  4.0E‐20  21886157  rs492602  MMP10  7.69E‐09 
Blood metabolite ratios 
(DSGEGDFXAEGGGVR/ADpSGEGDFXAEGGGVR) 
rs503279  0.89  1.0E‐13  24816252  rs492602  MMP10  7.69E‐09 
Pubertal anthropometrics (Single Height‐males)  rs281379  0.83  5.0E‐08  23449627  rs492602  MMP10  7.69E‐09 
Liver enzyme levels (alkaline phosphatase)  rs281377  0.70  1.0E‐15  22001757  rs492602  MMP10  7.69E‐09 
Urinary metabolites (H‐NMR features) (5.2125, 
Fucose) 
rs2287921  0.68  3.0E‐36  24586186  rs492602  MMP10  7.69E‐09 
Retinal vascular caliber (Retinal venular caliber)  rs2287921  0.68  2.0E‐25  21060863  rs492602  MMP10  7.69E‐09 
Urinary metabolites (H‐NMR features) (5.2825, 
Fucose) 
rs2287921  0.68  7.0E‐19  24586186  rs492602  MMP10  7.69E‐09 
Urinary metabolites (H‐NMR features) (5.2275, 
Fucose) 
rs2287921  0.68  1.0E‐12  24586186  rs492602  MMP10  7.69E‐09 
Dietary macronutrient intake (Fat)  rs838145  0.64  4.0E‐10  23636237  rs492602  MMP10  7.69E‐09 
Urinary metabolites (H‐NMR features) (5.2125, 
Fucose) 
rs2287921  0.89  3.0E‐36  24586186  rs33988101  LGALS3  3.57E‐09 
Retinal vascular caliber (Retinal venular caliber)  rs2287921  0.89  2.0E‐25  21060863  rs33988101  LGALS3  3.57E‐09 
Urinary metabolites (H‐NMR features) (5.2825, 
Fucose) 
rs2287921  0.89  7.0E‐19  24586186  rs33988101  LGALS3  3.57E‐09 
Urinary metabolites (H‐NMR features) (5.2275, 
Fucose) 
rs2287921  0.89  1.0E‐12  24586186  rs33988101  LGALS3  3.57E‐09 
Crohn's disease  rs281379  0.73  7.0E‐12  21102463  rs33988101  LGALS3  3.57E‐09 
Pubertal anthropometrics (Single Height‐males)  rs281379  0.73  5.0E‐08  23449627  rs33988101  LGALS3  3.57E‐09 
Dietary macronutrient intake (Fat)  rs838145  0.71  4.0E‐10  23636237  rs33988101  LGALS3  3.57E‐09 
Folate pathway vitamin levels (vitamin B12)  rs602662  0.68  3.0E‐20  19303062  rs33988101  LGALS3  3.57E‐09 
Folate pathway vitamin levels (Plasma Vitamin 
B12) 
rs602662  0.68  2.0E‐15  19744961  rs33988101  LGALS3  3.57E‐09 
Metabolic traits (SM‐11 + 2 other traits)  rs503279  0.68  4.0E‐20  21886157  rs33988101  LGALS3  3.57E‐09 
Blood metabolite ratios 
(DSGEGDFXAEGGGVR/ADpSGEGDFXAEGGGVR) 
rs503279  0.68  1.0E‐13  24816252  rs33988101  LGALS3  3.57E‐09 
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Blood metabolite ratios 
(ADSGEGDFXAEGGGVR/ADpSGEGDFXAEGGGVR
) 
rs601338  0.67  2.0E‐20  24816252  rs33988101  LGALS3  3.57E‐09 
Blood metabolite levels 
(ADpSGEGDFXAEGGGVR) 
rs601338  0.67  3.0E‐11  24816252  rs33988101  LGALS3  3.57E‐09 
Liver enzyme levels (gamma‐glutamyl 
transferase) 
rs516246  0.67  8.0E‐10  22001757  rs33988101  LGALS3  3.57E‐09 
Vitamin B12 levels  rs492602  0.66  5.0E‐17  18776911  rs33988101  LGALS3  3.57E‐09 
Cholesterol, total  rs492602  0.66  1.0E‐16  24097068  rs33988101  LGALS3  3.57E‐09 
Metabolite levels  rs4810479  1.00  2.0E‐42  22916037  rs4810479  KITLG  4.44E‐11 
Lipid metabolism phenotypes (HDL.large, 
fasting) 
rs6065904  0.72  4.0E‐40  19936222  rs4810479  KITLG  4.44E‐11 
Lipid metabolism phenotypes (L‐HDL‐L/M‐HDL‐
L) 
rs6065904  0.72  2.0E‐31  22286219  rs4810479  KITLG  4.44E‐11 
Inflammatory bowel disease  rs1569723  1.00  1.0E‐13  23128233  rs1569723  CD40  3.01E‐49 
Kawasaki disease  rs1569723  1.00  6.0E‐09  22446961  rs1569723  CD40  3.01E‐49 
Rheumatoid arthritis  rs4810485  0.99  3.0E‐09  20453842  rs1569723  CD40  3.01E‐49 
Rheumatoid arthritis (EA)  rs4239702  0.85  1.0E‐16  24390342  rs1569723  CD40  3.01E‐49 
Multiple sclerosis  rs2425752  0.64  5.0E‐10  21833088  rs1569723  CD40  3.01E‐49 
 
Pleiotropy of reported trait protein SNPs with findings from previously published GWAS studies. Publically available studies were investigated 
and associations were reported for proxy SNPs with r2 LD above 0.6 and association P‐value stronger than 5e‐8.  Other trait – the trait 
investigated in the published GWAS; Other SNP – the index SNP in the published GWAS; r2 (EUR 1000G) – linkage disequilibrium between Olink‐
improve study index SNP and the other SNP; Other P‐value – P‐value as reported in published GWAS; Pubmed ID – the pubmed ID of the 
published GWAS; Olink SNP – the index SNP of the Olink‐improve study; Olink Trait Protein – the trait protein associated in the Olink‐improve 
study; Olink P‐value – the P‐value as also reported in table 1. 
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Table	S3	
Gene  Protein Name  #samples 
below 
LOD 
CV%  Incl‐
uded 
Mean  
(SD) 
Median 
(IQR) 
V(G)/Vp 
 
R2   
ADM  Pro‐adrenomedullin  1  0.2  yes  0.87 
(0.029) 
0.87  
(0.85‐0.88) 
‐4.3% 
‐4.3% 
   
AGER  Advanced glycosylation end 
product‐specific receptor 
0  0.15  yes  0.66 
(0.043) 
0.67  
(0.64‐0.69) 
‐3.9% 
‐3.9% 
   
AGRP  Agouti‐related protein  0  0.17  yes  0.64 
(0.049) 
0.64  
(0.61‐0.67) 
‐2.5% 
‐0.9% 
   
BNP  Natriuretic peptides B  1434  0.2  yes  0.15  
(0.16) 
0.14  
(0.001‐0.22) 
0.8% 
6% 
   
CASP8  Caspase‐8  518    no           
CCL2  Monocyte chemoattractant 
protein 1 
0  0.2  yes  0.6  
(0.069) 
0.61  
(0.56‐0.65) 
3.3% 
10.9% 
   
CCL20  C‐C motif chemokine 20  0  0.15  yes  0.79  
(0.07) 
0.78  
(0.74‐0.83) 
34.4% 
74.1% 
   
CCL3  C‐C motif chemokine 3  0  0.17  yes  0.37 
(0.095) 
0.38  
(0.31‐0.44) 
6.3% 
17.3% 
   
CCL4  C‐C motif chemokine 4  0  0.13  yes  0.88 
(0.036) 
0.88  
(0.86‐0.9) 
‐2.9% 
‐2.1% 
   
CD40  Tumor necrosis factor 
receptor superfamily member 
5 
0  0.15  yes  0.97  
(0.03) 
0.96  
(0.95‐0.98) 
‐4.1% 
‐4.1% 
   
CD40LG  CD40 ligand  0  0.2  yes  0.77  
(0.1) 
0.76  
(0.69‐0.84) 
‐3.5% 
‐3.1% 
   
CHI3L1  Chitinase‐3‐like protein 1  0  0.16  yes  0.8  
(0.066) 
0.8  
(0.76‐0.84) 
1.1% 
6.6% 
   
CSF1  Macrophage colony‐
stimulating factor 1 
0  0.15  yes  0.95 
(0.015) 
0.95  
(0.94‐0.96) 
7.6% 
20.1% 
   
CSTB  Cystatin‐B  0  0.16  yes  0.74  
(0.04) 
0.74  
(0.71‐0.76) 
‐3.7% 
‐3.7% 
   
CTSD  Cathepsin D  1  0.15  yes  0.87  
(0.03) 
0.87  
(0.85‐0.89) 
3.4% 
11.3% 
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CTSL1  Cathepsin L1  0  0.16  yes  0.78 
(0.034) 
0.78  
(0.75‐0.8) 
‐4.1% 
‐4.1% 
   
CX3CL1  Fractalkine  0  0.26  yes  0.73 
(0.045) 
0.73  
(0.7‐0.76) 
‐0.6% 
2.9% 
   
CXCL1  Growth‐regulated alpha 
protein 
0  0.15  yes  0.79 
(0.093) 
0.8  
(0.73‐0.86) 
1.4% 
7.0% 
   
CXCL16  C‐X‐C motif chemokine 16  0  0.17  yes  0.58 
(0.041) 
0.58  
(0.56‐0.61) 
10.9% 
26.6% 
   
CXCL6  C‐X‐C motif chemokine 6  0  0.15  yes  0.78 
(0.066) 
0.78  
(0.74‐0.83) 
‐1.8% 
0.5% 
   
DKK1  Dickkopf‐related protein 1  0  0.13  yes  0.72 
(0.063) 
0.72  
(0.68‐0.77) 
‐0.8% 
2.7% 
   
EGF  Pro‐epidermal growth factor  0  0.15  yes  0.65  
(0.15) 
0.66  
(0.55‐0.76) 
‐4.1% 
‐4.1% 
   
ESM1  Endothelial cell‐specific 
molecule 1 
0  0.17  yes  0.58 
(0.053) 
0.58  
(0.54‐0.61) 
‐0.1% 
4.1% 
   
F2R  Proteinase‐activated receptor 
1 
0  0.18  yes  0.84 
(0.034) 
0.84  
(0.82‐0.86) 
3.4% 
11.4% 
   
F3  Tissue factor  0  0.18  yes  0.81  
(0.03) 
0.81  
(0.79‐0.83) 
‐3.8% 
‐3.8% 
   
FABP4  Fatty acid‐binding protein, 
adipocyte 
4  0.2  yes  0.48 
(0.096) 
0.49  
(0.43‐0.55) 
2.5% 
9.4% 
   
FAS  Tumor necrosis factor 
receptor superfamily member 
6 
0  0.13  yes  0.89 
(0.023) 
0.9  
(0.88‐0.91) 
8% 
21% 
   
FGF23  Fibroblast growth factor 23  0  0.17  yes  0.46  
(0.08) 
0.47  
(0.41‐0.51) 
‐3.9% 
‐3.9% 
   
FIGF  Vascular endothelial growth 
factor D 
0  0.19  yes  0.84 
(0.038) 
0.84  
(0.82‐0.86) 
6.1% 
16.6% 
   
FST  Follistatin  0  0.18  yes  0.74 
(0.041) 
0.74  
(0.71‐0.77) 
0.7% 
5.7% 
   
GAL  Galanin peptides  0  0.15  yes  0.72  
(0.06) 
0.73  
(0.69‐0.76) 
3.6% 
11.6% 
   
GDF15  Growth/differentiation factor  0  0.13  yes  0.99  0.99   ‐0.7%     
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15  (0.027)  (0.97‐1.0)  2.8% 
GH1  Somatotropin  0  0.15  yes  0.92  
(0.11) 
0.93  
(0.84‐1.0) 
‐3.7% 
‐3.2% 
   
HAVCR1  Hepatitis A virus cellular 
receptor 1 
0  0.16  yes  0.78  
(0.06) 
0.78  
(0.74‐0.82) 
‐2.7% 
‐0.8% 
   
HBEGF  Proheparin‐binding EGF‐like 
growth factor 
0  0.18  yes  0.67 
(0.042) 
0.67  
(0.65‐0.7) 
11% 
26.6% 
   
HGF  Hepatocyte growth factor  0  0.13  yes  0.83  
(0.03) 
0.83  
(0.82‐0.85) 
2.8% 
10% 
   
HSPB1  Heat shock protein beta‐1  303  0.16  yes  0.34  
(0.24) 
0.32  
(0.14‐0.53) 
‐0.7% 
2.8% 
   
IKBKG  NF‐kappa‐B essential 
modulator 
163  0.22  yes  0.43  
(0.22) 
0.43  
(0.29‐0.58) 
1.3% 
7% 
   
IL16  Pro‐interleukin‐16 [Cleaved 
into: Interleukin‐16 
0  0.2  yes  0.63 
(0.053) 
0.63  
(0.6‐0.67) 
6.4% 
17.3% 
   
IL18  Interleukin‐18  0  0.12  yes  1.0  
(0.026) 
1.0 
(0.99‐1.01) 
15.6% 
36.1% 
   
IL1RL1  Interleukin‐1 receptor‐like 1  0  0.13  yes  0.54 
(0.072) 
0.55  
(0.5‐0.59) 
6.4% 
17.3% 
   
IL1RN  Interleukin‐1 receptor 
antagonist protein 
0    no           
IL27  Interleukin‐27 subunit alpha  0  0.2  yes  0.42 
(0.071) 
0.43  
(0.38‐0.47) 
‐3.3% 
‐2.3% 
   
IL4  Interleukin‐4  2559    no           
IL6  Interleukin‐6  0  0.13  yes  0.7  
(0.078) 
0.69  
(0.65‐0.74) 
‐1.3% 
1.7% 
   
IL6R  Interleukin‐6 receptor subunit 
alpha 
0  0.14  yes  0.85 
(0.029) 
0.85  
(0.83‐0.87) 
‐3.7% 
‐3.7% 
   
IL8  Interleukin‐8  1  0.15  yes  0.73 
(0.055) 
0.73  
(0.69‐0.76) 
3.6% 
11.9% 
   
ITGB1BP2  Integrin beta‐1‐binding 
protein 2 
1788    no           
KITLG  Kit ligand  0  0.12  yes  0.87 
(0.031) 
0.87  
(0.85‐0.89) 
2.9% 
10.3% 
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KLK11  Kallikrein‐11  0  0.19  yes  0.72 
(0.039) 
0.72  
(0.7‐0.75) 
12.7% 
30.3% 
   
KLK6  Kallikrein‐6  0  0.15  yes  0.83 
(0.028) 
0.83  
(0.81‐0.85) 
‐1.2% 
1.7% 
   
LEP  Leptin  82  0.18  yes  0.47  
(0.16) 
0.5  
(0.39‐0.59) 
‐4.2% 
‐4.2% 
   
LGALS3  Galectin‐3  0  0.16  yes  0.78  
(0.03) 
0.78  
(0.76‐0.8) 
‐4% 
‐4% 
   
MB  Myoglobin  3  0.17  yes  0.74 
(0.048) 
0.74  
(0.71‐0.77) 
7.6% 
19.6% 
   
MMP1  Interstitial collagenase  7  0.19  yes  0.49  
(0.19) 
0.51  
(0.4‐0.61) 
54.8% 
114.2% 
   
MMP10  Stromelysin‐2  0  0.16  yes  0.82 
(0.043) 
0.82  
(0.79‐0.85) 
1.6% 
7.6% 
   
MMP12  Macrophage metalloelastase  0  0.14  yes  0.85 
(0.043) 
0.85  
(0.82‐0.88) 
‐3.8% 
‐3.8% 
   
MMP3  Stromelysin‐1  20  0.13  yes  ‐0.027  
(0.3) 
0.031  
(‐0.15‐0.17) 
6.3% 
17.3% 
   
MMP7  Matrilysin  1  0.2  yes  0.83  
(0.11) 
0.86  
(0.76‐0.92) 
5.9% 
16.5% 
   
MPO  Myeloperoxidase  0  0.15  yes  0.57  
(0.04) 
0.57  
(0.54‐0.59) 
‐4.1% 
‐4.1% 
   
MUC16  Mucin‐16  1  0.22  yes  0.71 
(0.076) 
0.72  
(0.67‐0.76) 
‐4.2% 
‐4.2% 
   
NGF  Beta‐nerve growth factor  510  0.18  yes  ‐0.059 
(0.13) 
‐0.064  
(‐0.16‐0.029) 
0.5% 
5.5% 
   
NPPB  Pro‐Natriuretic peptides B  135  0.2  yes  0.56  
(0.12) 
0.57  
(0.48‐0.65) 
7.2% 
19.1% 
   
OLR1  Oxidized low‐density 
lipoprotein receptor 1 
0  0.17  yes  0.67 
(0.059) 
0.66  
(0.63‐0.7) 
7.1% 
18.6% 
   
PAPPA  Pappalysin‐1  60  0.17  yes  0.32  
(0.14) 
0.34  
(0.25‐0.41) 
4.6% 
13.8% 
   
PDGFB  Platelet‐derived growth factor 
subunit B 
0  0.13  yes  0.82 
(0.091) 
0.83  
(0.77‐0.88) 
‐3.9% 
‐3.9% 
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PECAM1  Platelet endothelial cell 
adhesion molecule 
0  0.2  yes  0.78 
(0.032) 
0.77  
(0.75‐0.8) 
‐3.1% 
‐2.6% 
   
PGF  Placenta growth factor  1  0.15  yes  0.88 
(0.024) 
0.88  
(0.87‐0.9) 
6.5% 
17.7% 
   
PLAT  Tissue‐type plasminogen 
activator 
0  0.24  yes  0.89 
(0.037) 
0.89  
(0.87‐0.91) 
‐4% 
‐4% 
   
PLAUR  Urokinase plasminogen 
activator surface receptor 
0  0.14  yes  1  
(0.015) 
1.0  
(0.99‐1.01) 
4% 
12.5% 
   
PRL  Prolactin  3  0.15  yes  0.62 
(0.081) 
0.62  
(0.57‐0.67) 
8.8% 
22.1% 
   
PTX3  Pentraxin‐related protein 
PTX3 
914    no           
REN  Renin  0  0.17  yes  0.87 
(0.056) 
0.87  
(0.83‐0.91) 
0.9% 
6% 
   
RETN  Resistin  0  0.16  yes  0.84 
(0.036) 
0.84  
(0.82‐0.87) 
21% 
47% 
   
RNASE3  Eosinophil cationic protein  2  0.16  yes  0.77 
(0.053) 
0.77  
(0.74‐0.8) 
‐2.8% 
‐1.8% 
   
S100A12  Protein S100‐A12  669    no           
SELE  E‐selectin  0  0.16  yes  0.77 
(0.052) 
0.77  
(0.73‐0.8) 
5.5% 
15.6% 
   
SELPLG  P‐selectin glycoprotein ligand 
1 
1081    no           
SIRT2  NAD‐dependent protein 
deacetylase sirtuin‐2 
585    no           
SPON1  Spondin‐1  0  0.17  yes  0.69 
(0.033) 
0.69  
(0.67‐0.71) 
‐3.6% 
‐3.6% 
   
SRC  Proto‐oncogene tyrosine‐
protein kinase Src 
0  0.21  yes  0.74  
(0.12) 
0.77  
(0.65‐0.85) 
‐2.8% 
‐1.5% 
   
TEK  Angiopoietin‐1 receptor  0  0.14  yes  0.82 
(0.023) 
0.82  
(0.8‐0.83) 
‐4.2% 
‐4.2% 
   
THBD  Thrombomodulin  0  0.16  yes  1.0  
(0.018) 
1.0  
(0.99‐1) 
2% 
8.4% 
   
TNFRSF10B  Tumor necrosis factor  0  0.24  yes  0.19   0.26   0.9%     
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receptor superfamily member 
10B 
(0.21)  (0.086‐0.33)  6.4% 
TNFRSF11B  Osteoprotegerin  1  0.13  yes  1  
(0.023) 
1  
(0.99‐1) 
10.7% 
26.2% 
   
TNFRSF1A  Tumor necrosis factor 
receptor superfamily member 
1A 
0    no           
TNFRSF1B  Tumor necrosis factor 
receptor superfamily member 
1B 
6  0.2  yes  0.63 
(0.071) 
0.64  
(0.59‐0.68) 
6.6% 
17.9% 
   
TNFSF10  Tumor necrosis factor ligand 
superfamily member 10 
0  0.16  yes  0.35  
(0.11) 
0.36  
(0.28‐0.43) 
‐3.9% 
‐3.9% 
   
TNFSF11  RANK ligand  0  0.15  yes  1.1  
(0.014) 
1.1  
(1.1‐1.1) 
13.6% 
32.1% 
   
TNFSF14  Tumor necrosis factor ligand 
superfamily member 14 
0  0.15  yes  0.73 
(0.038) 
0.73  
(0.7‐0.75) 
3.5% 
11.4% 
   
VEGFA  Vascular endothelial growth 
factor A 
0  0.13  yes  1  
(0.017) 
1  
(1‐1) 
0.5% 
5.4% 
   
XPNPEP2  Xaa‐Pro aminopeptidase 2  462  0.19  yes  0.47  
(0.14) 
0.48  
(0.33‐0.58) 
‐0.1% 
4.1% 
   
 
Overview of all 92 measured proteins, with quality control parameters, descriptive statistics and heritability estimates. All descriptive statistics 
are reported on the log10‐transformed data that was used for analysis; #samples below LOD – the number of samples below limit of detection; 
CV% ‐ coefficient of variation; Included – final choice on inclusion in analysis; Mean (SD) – mean and standard‐deviation; Median (IQR) – median 
and inter‐quartile range; V(G)/Vp– The GCTA calculated narrow‐sense heritability. Missing values correspond to GCTA invertable matrix errors  ‐ 
meaning that too few samples were available for the V(G)/Vp estimation ; R2 – description still missing. 
